
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the Month of August 2013

ELRON ELECTRONIC INDUSTRIES LTD.
(Translation of Registrant's Name into English)

3Azrieli Center, Triangle Building, 42nd Floor, Tel Aviv • ISRAEL
(Address of Principal Corporate Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark if the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-(2): 82-_____

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ELRON ELECTRONIC INDUSTRIES LTD.
(Registrant)

By: /s/ Yaron Elad

Yaron Elad
VP & CFO

Dated: August 13, 2013

Elron Electronic Industries Ltd.
("Elron" or the "Company")

English Translation of Quarterly Report
for the Second Quarter of 2013

Part I

Material Changes and Updates that Occurred in the Company's
Business in the Three Months Ended June 30, 2013

Details according to Regulation 39A of the Israel Securities Regulations (Periodic and Immediate Reports), 1970

In this section:

"Board of Directors Report"	English Translation of Elron's Board of Directors Report for the Second Quarter of 2013, included in Part II of this report.
"Financial Statements"	English Translation of Elron's Interim Consolidated Financial Statements for the Six Months Ended June 30, 2013, included in Part III of this report.
"20-F Annual Report"	Elron's Annual Report for 2012 filed with the SEC on Form 20-F.

The rest of the terms in this report shall have the meaning ascribed to them in the 20-F Annual Report, unless stated explicitly otherwise.

In accordance with reporting requirements in Israel, Elron filed an annual report for 2012 in Hebrew with the Israeli Securities Authority ("ISA Annual Report"), simultaneously with its 20-F Annual Report. For the convenience of the Company's U.S. based shareholders, in translating Part I of this report from Hebrew to English, changes and updates are given in reference to the 20-F Annual Report, rather than its ISA Annual Report filed in Hebrew.

The matters described below are in addition to the developments and changes that occurred in the second quarter of 2013, which were described in Part I of the Company's Quarterly Report for the First Quarter of 2013.

1. **Item 4A – Information on the Company: History and Development of the Company**

1.1. **Investments**

In the first half of 2013, Elron (directly and indirectly through RDC and Navitrio) invested approximately \$4.5 million in group companies. For further details see Section 1.4 of the Board of Directors Report and Note 3 to the Financial Statements.

1.2. **Transfer of Holdings in Navitrio to RDC**

In July 2013, subsequent to the date of this report, Elron transferred its holdings in Navitrio to RDC, in consideration for \$5 million (the sum Elron invested in Navitrio since it was established in 2011), subject to adjustments. Subsequent to the transfer and a \$1 million investment by RDC in Navitrio in July 2013, subsequent to the date of this report, Elron holds approximately 44% of Navitrio indirectly, and approximately 87% on a consolidated basis.

2. **Item 4B – Business Overview: Our Main Group Companies**

2.1. **Given Imaging**

In July 2013, subsequent to the date of this report, Given Imaging announced that the second generation of its PillCam COLON was cleared by Japan's Pharmaceuticals & Medical Devices Agency (PMDA) for diagnosis of colonic disease when colonoscopy is required but difficult to conduct, including patients unwilling or unable to undergo colonoscopy. In addition, Given Imaging noted in its announcement, among other things, that it expects reimbursement in Japan to become effective during the first half of 2014, subject to government discretion.

Given Imaging's abovementioned estimate is forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and is based on information existing in Given Imaging on the date of this report. This estimate, in all or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors which may affect this are: the position of the parties responsible for approving reimbursement for the PillCam COLON, difficulties in manufacturing, marketing and/or selling the PillCam COLON in Japan, inability to realize technologies, modifications in technologies, business plan, goals and/or strategy.

In August 2013, subsequent to the date of this report, Given Imaging announced that the U.S. Food and Drug Administration (FDA) granted clearance for the next generation PillCam, SB 3, to detect and monitor small bowel abnormalities.

2.2. Pocared

In July 2013, subsequent to the date of this report, Pocared commenced urine sample collection for the trial it is conducting in order to test the efficacy of the first application of its system, urinary tract infection (UTI) diagnosis. The trial is expected to support its submission to the FDA for marketing clearance. The trial is being conducted at five of the world's leading medical centers. Pocared expects to complete the trial during 2013.

Pocared's abovementioned estimates are forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and are based on Pocared's estimates of its development and business potential, on Pocared's intentions and strategy as of the date of this report, and on information existing in Pocared on the date of this report. These estimates, in all or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors which may affect this are: developments in Pocared's field of operation, failure to obtain regulatory approval to continue product development, failure to achieve goals, trial results, inability to realize technologies, modifications in technologies, business plan, goals and/or strategy, or if any of the risk factors associated with the course of the trial and its results take place.

Ari Bronshtein
CEO

Yaron Elad
CFO

August 13, 2013, Tel Aviv, Israel

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1. Board of Directors' Analysis of the Company's Business

1.1. Company Description

1.1.1. General

Elron Electronic Industries Ltd. ("Elron", the "Company") is an operational holding company focused on building technology companies. Elron's group of companies includes companies at various stages of development that are engaged in a variety of technology fields, such as developing medical devices and others. Elron's principal shareholder is Discount Investment Corporation Ltd. ("DIC") (50.32%), a company controlled by IDB Development Corporation Ltd. ("IDB").

Elron operates through consolidated companies (companies controlled by Elron and whose financial statements are consolidated with Elron's financial statements), associates (companies over which Elron has significant influence and which are included in its financial statements using the equity method), and other companies over which the Company does not have significant influence (included in the financial statements based on fair value) (the "Group Companies").

For details on the accounting method applied to the Group Companies in Elron's financial statements, Elron's holding percentage in the Group Companies, and their carrying value, see the annex to the Company's interim consolidated financial statements as of June 30, 2013 (the "Financial Statements").

The Financial Statements were prepared in accordance with International Financial Reporting Standards ("IFRS").

1.1.2. Main goal

Elron's main goal is to build value for its shareholders by enhancing and exiting its Group Company holdings (whether through their sale or through the public listing of their shares), while simultaneously seeking new investment opportunities in technology companies.

1.1.3. Strategy

In order to achieve this goal, Elron operates according to the following business strategy:

- Investing in Israeli or Israeli related technology companies.
- Identifying and exploiting investment opportunities with significant exit potential.
- Focusing on investments which afford Elron influence and active involvement in their management.
- Actively enhancing the Group Companies' value by providing guidance and hands-on assistance to their management.
- Exploiting opportunities to exit Group Companies.

1.1.4. RDC

As part of its business strategy, Elron examines a broad range of cooperation and investment proposals, including through RDC – Rafael Development Corporation Ltd. ("RDC"), an Elron subsidiary.

RDC has first rights to commercialize military technologies developed by Rafael – Advanced Defense Systems Ltd. ("Rafael") in civilian markets. RDC seeks to identify technology projects and invest in companies that will either make civilian use of Rafael's military technologies or which will benefit from Rafael's technology, know-how and expertise.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1.1.5. Group companies

Elron's main Group Companies and its holding percentage in them as of the date of filing this report are as follows:

- **RDC (50.1%)** - See description in section 1.1.4 above.
- **Given Imaging Ltd. (22% directly, and 8% by RDC) ("Given Imaging")** - Given Imaging develops, manufactures, and markets diagnostic products for visualizing and detecting disorders of the gastrointestinal tract, among them the PillCam capsule, an ingestible capsule used to visualize the gastrointestinal tract through a miniaturized video camera contained in it. Given Imaging's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange.
- **Pocared Diagnostics Ltd. (41%) ("Pocared")** - Pocared is developing a real-time and automated system for infectious diseases diagnosis using optical technology, intended for use by major microbiological laboratories and hospitals, as an alternative to current microbiological practice of bacteria culturing. The system is designed to reduce the average diagnostic time and significantly increase output in comparison with current diagnostic practice.
- **BrainsGate Ltd. (30%) ("BrainsGate")** - BrainsGate is developing a system for treating ischemic stroke. The system operates by electrically stimulating a nerve center located behind the nasal cavity using a miniature implantable electrode, in order to increase blood flow to the brain. The system is intended to significantly lengthen the approved stroke treatment window to 24 hours post-symptom onset, and to provide a more effective treatment than is currently available.

See Item 4B – "Business Overview" of the Company's Annual Report for 2012 filed on Form 20-F with the Securities and Exchange Commission ("Elron's 2012 Annual Report") for details on the criteria for classifying a Group Company as a main company.

Additional Elron Group Companies and its holding percentage in them as of the date of filing this report are, among others, as follows:

- **Kyma Medical Technologies Ltd. (73% by RDC) ("Kyma")** - Kyma is developing a remote patient monitoring system for chronic heart failure patients, in order to enable early treatment of pulmonary edema and reduce the need for unnecessary hospitalizations.
- **Notal Vision Inc. (23%) ("Notal Vision")** - Notal Vision develops, manufactures, and provides a system and services for remote monitoring of AMD patients at risk of vision loss, for the early detection of critical visual changes.
- **CartiHeal (2009) Ltd. (24%) ("CartiHeal")** - CartiHeal is developing implants for repairing cartilage and osteochondral defects in loadbearing joints, such as the knee and ankle. The implant's unique structure, comprising a coral scaffold with biological modifications, causes the implant to biodegrade, and promotes the regeneration of native cartilage in its place. CartiHeal's first product is indicated for treatment of cartilage defects in the knee.
- **Navitrio Ltd. (87% by RDC) ("Navitrio")** - Navitrio is an investment venture that incubates projects and invests in companies in the digital field. Navitrio's holdings as of the date of filing this report include: Cloudyn Software Ltd. (46%) ("Cloudyn"), which is developing solutions for the optimization of cloud computing costs and resources; Numbeez Ltd. (39%) ("Numbeez"), which is developing a micro-blogging platform that helps users create, track and share the interesting numbers in their lives; and Pose POS Ltd. (43%) ("POSE"), which is developing an online cash register, inventory management, and retail website management system.
- **Jordan Valley Semiconductors Ltd. (19%) ("Jordan Valley")** - Jordan Valley develops, manufactures, and provides metrology solutions for manufacturing process control in the microelectronics industry.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1.1.6. Factors affecting the results of operations and capital resources

As a holding company, Elron's operating results mainly derive from:

- its share in the net losses of Group Companies;
- gains or losses from exit transactions or changes in holdings, and revaluation of investments recorded based on fair value;
- its corporate activities.

Elron's capital resources in any given period are primarily affected by:

- the extent of its investments;
- proceeds from exit transactions;
- available credit lines or loans;
- dividends distributed to shareholders or received from Group Companies.

Most of the Group Companies are technology companies which have not yet generated significant revenues, if at all, and which invest considerable resources in development and record losses. As a result, Elron has recorded and is expected to continue to record losses in respect of their ongoing operations, based on the accounting method applied to them in the Financial Statements.

The technology field in which the Group Companies operate are characterized by a high degree of risk. The Group Companies' success is dependent, among other things, upon: their intellectual property and ability to protect it; their ability to raise financing; their ability to successfully complete their products' development and receive regulatory clearance to market them, including through clinical trials; their ability to make the transition from development to manufacturing stages; their ability to market their products on a significant commercial scale; their ability to develop additional products; and their ability to successfully compete in the markets in which they operate.

Elron's ability to effect exit transactions at significant values is affected, among other things, by economic conditions, market conditions in the hi-tech industry, the status of the venture capital industry, the status of the capital markets, various contractual and regulatory restrictions, and is also dependent on management's ability to successfully lead exit transactions.

In addition, Elron's and the Group Companies' ability to obtain external financing is affected by economic conditions, the status of the capital markets, and the status of the venture capital industry.

1.2. Description of Operations in the Period of this Report and Subsequently

1.2.1. Investments

- In the first half of 2013, Elron (directly and indirectly through RDC and Navitrio) invested approximately \$4.5 million in the Group Companies. For further details see section 1.4 below and Note 3 to the Financial Statements.

1.2.2. Developments in the Company and Group Companies

- **Given Imaging's PillCam SB 3 Cleared for Marketing in the U.S.** - In August 2013, subsequent to the date of this report, Given Imaging announced that the U.S. Food and Drug Administration (FDA) granted clearance for the next generation PillCam, SB 3, to detect and monitor small bowel abnormalities.
- **Given Imaging's PillCam COLON Cleared for Marketing in Japan** - In July 2013, subsequent to the date of this report, Given Imaging announced that the second generation its PillCam COLON was cleared by Japan's Pharmaceuticals & Medical Devices Agency (PMDA) for diagnosis of colonic disease when colonoscopy is required but difficult to conduct, including patients unwilling or unable to undergo colonoscopy. In addition, Given Imaging noted in its announcement, among other things, that it expects reimbursement in Japan to become effective during the first half of 2014, subject to government discretion.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Given Imaging's abovementioned estimate is forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and is based on information existing in Given Imaging on the date of this report. This estimate, in all or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors which may affect this are: the position of the parties responsible for approving reimbursement for the PillCam COLON, difficulties in manufacturing, marketing and/or selling the PillCam COLON in Japan, inability to realize technologies, modifications in technologies, business plan, goals and/or strategy.

- **Transfer of Holdings in Navitrio to RDC** - In July 2013, subsequent to the date of this report, Elron transferred its holdings in Navitrio to RDC, in consideration for \$5 million (the sum Elron invested in Navitrio since it was established in 2011), subject to adjustments. Subsequent to the transfer and a \$1 million investment by RDC in Navitrio in July 2013, subsequent to the date of this report, Elron holds approximately 44% of Navitrio indirectly, and approximately 87% on a consolidated basis.
- **Update on Pocared's FDA Trial** - In July 2013, subsequent to the date of this report, Pocared commenced urine sample collection for the trial it is conducting in order to test the efficacy of the first application of its system, urinary tract infection (UTI) diagnosis. The trial is expected to support its submission to the FDA for marketing clearance. The trial is being conducted at five of the world's leading medical centers. Pocared expects to complete the trial during 2013.

Pocared's abovementioned estimates are forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and are based on Pocared's estimates of its development and business potential, on Pocared's intentions and strategy as of the date of this report, and on information existing in Pocared on the date of this report. These estimates, in all or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors which may affect this are: developments in Pocared's field of operation, failure to obtain regulatory approval to continue product development, failure to achieve goals, trial results, inability to realize technologies, modifications in technologies, business plan, goals and/or strategy, or if any of the risk factors associated with the course of the trial and its results take place.

- **Update on BrainsGate's FDA Trial** - Further to Item 4B of Elron's 2012 Annual Report regarding BrainsGate's estimates regarding the timing of its clinical trial's completion, in light of volatility in the rate of patient recruitment, and the uncertainty arising from such volatility as to the rate of future patient recruitment, BrainsGate estimates that it may complete the trial in the fourth quarter of 2013 or the first half of 2014, upon its completion on approximately 450 patients. To date, BrainsGate has enrolled 317 patients at 65 medical centers in the United States, Europe and Asia.

BrainsGate's above estimates are forward-looking in nature, as defined in Israel Securities Law, 5728-1968, and are based on BrainsGate's estimations of its recruitment rate potential as of the date of filing this report, and information existing in BrainsGate on the date of filing this report. These estimates, in whole or in part, may not materialize, or may materialize in a manner materially different than expected. The principal factors which may affect this are developments in BrainsGate's field of operation, failure to obtain regulatory approvals to continue development, failure to meet goals, failure to recruit the large number of candidates necessary to complete the trial, trial results, inability to realize technologies, modifications in technologies, modifications in business plan, goals and/or strategy, or if any risk associated with the course of the trial and its results occurs.

- **DIC Considering Sale of Controlling Block of Given Imaging** - In January 2013, DIC announced that it intends to seek and consider possibilities to sell the controlling block of Given Imaging, through the sale of all its shares of Given Imaging, directly and indirectly through Elron (approximately 45%). There can be no assurance as to the identification or realization of such concrete possibility or as to the timing or terms of a transaction in this matter. Insofar as such a possibility is identified, Elron intends to consider participating in it. Any such transaction, if it were to occur, would require the appropriate corporate approvals of Elron.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1.2.3. Financing

- **Credit Line Extension** - In April 2013, Elron and Silicon Valley Bank entered into a credit line extension agreement in the amount of \$25 million, including \$10 million which is available until December 31, 2013 and an additional \$15 million available until October 30, 2014. The credit line was extended in order to ensure and diversify additional sources of financing towards continued investing in the Group Companies and in new companies and to finance Elron's ongoing operations, and due to the partial utilization of the previous credit line which was about to expire. (For further details see section 1.4 below).
- As of the date of filing this report, Elron's and RDC's non-consolidated cash and cash equivalents amounted to approximately \$24.5 million and \$13.3 million, respectively. At this date Elron has a \$4 million debt balance, and RDC has no debt.

1.3. Results of Operations

1.3.1. Elron's main operating results

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012	For the year ended December 31, 2012
	unaudited				audited
	\$ thousands				
Net income (loss) attributable to Elron's shareholders	(7,633)	(3,098)	(2,171)	3,120	4,357
Net income (loss) per share attributable to Elron's shareholders (in \$)	(0.29)	(0.13)	(0.09)	0.09	0.09

As previously mentioned, the income and loss attributable to Elron's shareholders mainly comprises of: I) Elron's share in the losses of Group Companies, II) gains and losses from exit transactions, revaluation of investments, and changes in holdings, III) corporate operating expenses:*

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012	For the year ended December 31, 2012
	\$ thousands				
Losses in respect of Group Companies:					
Elron's share in net losses of Group Companies	(5,060)	(6,080)	(1,538)	(2,618)	(10,597)
Excess cost amortization	(2,030)	(2,367)	(1,010)	(1,115)	(4,414)
Impairment of investments in Group Companies and financial assets	-	(1,318)	-	(1,186)	(1,125)
Total	(7,090)	(9,765)	(2,548)	(4,919)	(16,136)
Gain from exit transactions, changes in holdings, and revaluation of investments (net of tax)					
	1,911	9,007	1,678	9,514	24,755
Corporate operating expenses	(2,034)	(1,998)	(1,042)	(998)	(3,873)

* The results summarized in the table are presented net of non-controlling interest.

I) Losses in respect of Group Companies

Elron's share in the net losses of Group Companies:

As previously mentioned, most of the Group Companies are technology companies which have not yet generated significant revenues, if at all, and which invest considerable resources in research and development and in marketing activities. According to accounting principles, these companies' investments in the development of their products are recorded as they occur in their statement of income as an increase in R&D expenses (insofar as these expenses are not capitalized as intangible assets as is permitted, according to accounting principles, only when technological feasibility has been established). Therefore, as the Group Companies increase their investments in order to develop their products and advance their business, they cause Elron to record greater losses in respect of its share in their losses.

The loss Elron recorded in the second quarter and first half of 2013 in respect of its share in the net losses of Group Companies (net of non-controlling interest) resulted mainly from the losses of Pocared, BrainsGate, Navitrio, CartiHeal, and Kyma.

The loss Elron recorded in the second quarter and first half of 2012 in respect of its share in the net losses of Group Companies (net of non-controlling interest) resulted mainly from the losses of Navitrio, NuLens Ltd. ("NuLens"), Kyma, BrainsGate and Pocared.

Excess cost amortization:

The Company records amortization expenses in respect of excess cost attributed to investments in Group Companies, which are usually generated upon investment in such companies or when the accounting method applied is changed from the equity method to consolidation.

Excess cost amortization expenses in the second quarter and first half of 2013 and 2012 were recorded primarily in respect of excess costs attributed to the Company's holding in Given Imaging.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Impairment charges of investments in Group Companies and financial assets:

At each reporting date the Company examines whether there is any evidence that would indicate that its investment in Group Companies and financial assets is impaired.

In the first half of 2013, no impairment charges were recorded.

In the second quarter of 2012, an impairment charge was recorded in respect of the Company's holding in Wave Systems Corp. ("Wave") shares traded on the Nasdaq, due to a decrease in their share price. (In the third quarter of 2012, the entire holding in Wave shares was sold, except for those shares deposited in escrow with their receipt in the sale of Safend Ltd. ("Safend") in September 2011).

II) Gain (Loss) from exit transactions, changes in holdings, and revaluation of investments

Gains from exit transactions, changes in holdings, and revaluation of investments recorded at fair value in the second quarter and first half 2013 resulted mainly from:

- A \$1,287 thousand gain recorded in the second quarter due to an increase in Notal Vision's fair value;
- An \$810 thousand loss recorded in the second quarter due to a decrease in Jordan Valley's fair value;
- A \$1,201 and \$1,399 thousand gain (net of non-controlling interest) recorded in the second quarter and first half, respectively, from a change in the Company's holding in Given Imaging as a result of options granted to Given Imaging employees having been exercised or having expired.

Gains from exit transactions, changes in holdings, and revaluation of investments recorded at fair value in the second quarter and first half 2012 resulted mainly from:

- An approximately \$8,500 thousand gain (net of non-controlling interest) recorded in the second quarter as a result of additional consideration received for the sale of Medingo Ltd. ("Medingo") completed in 2010;
- An approximately \$1,000 thousand gain recorded in the second quarter due to an increase in Jordan Valley's fair value;
- An approximately \$208 and \$715 thousand loss (net of non-controlling interest) recorded in the second quarter and first half, respectively, from a decrease in the Company's holding in Given Imaging as a result of options granted to Given Imaging employees having been exercised or having expired.

III) Corporate operating expenses

Corporate operating expenses include general and administrative expenses.

There was no material change in corporate operating expenses in the first half of 2013 as compared with the first half of 2012.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1.3.2. Consolidated statements of profit and loss

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012	For the year ended December 31, 2012
	unaudited		unaudited		audited
	\$ thousands				
Gain from disposal and revaluation of group companies, and changes in holdings, net	2,268	16,082	1,921	16,595	39,426
Financial income	502	917	193	364	1,241
Total income	2,770	16,999	2,114	16,959	40,667
Research and development expenses, net	2,283	3,129	987	1,697	6,869
Selling and marketing expenses	218	264	70	155	905
General and administrative expenses	2,952	4,133	1,463	2,233	7,190
Equity in losses of associates, net	5,213	4,991	1,639	1,807	8,357
Financial expenses	370	1,834	244	1,303	2,052
Other expenses (income), net	17	500	12	500	(282)
Total costs and expenses	11,053	14,851	4,415	7,695	25,091
Income (Loss) before taxes on income	(8,283)	2,148	(2,301)	9,264	15,576
Tax benefit	-	(161)	-	(161)	(262)
Net income (loss)	(8,283)	2,309	(2,301)	9,425	15,838
Net income (loss) attributable to the Company's shareholders	(7,633)	(3,098)	(2,171)	3,120	4,357
Net income (loss) attributable to non-controlling interest	(650)	5,407	(130)	6,305	11,481
Basic and diluted net income (loss) per share attributable to the Company's shareholders (in \$)	(0.29)	(0.13)	(0.09)	0.09	0.09

1.3.3. Analysis of the consolidated statements of profit and loss

Gain from disposal and revaluation of Group Companies and changes in holdings, net

In the second quarter and first half of 2013, the gain from disposal and revaluation of Group Companies and changes in holdings, net, amounted to \$1,921 and \$2,267 thousand, respectively, and mainly resulted from: a \$1,287 thousand gain recorded in the second quarter due to an increase in Notal Vision's fair value, mainly due to progress made in the clinical trials it is conducting; an \$810 thousand loss recorded in the second quarter due to a decrease in Jordan Valley's fair value; and a \$1,444 and \$1,745 thousand gain recorded in the second quarter and first half, respectively, from a change in the Company's holding in Given Imaging as a result of options granted to Given Imaging employees having been exercised or having expired.

In the second quarter and first half of 2012, gains from disposal and revaluation of Group Companies and changes in holdings, net, amounted to \$16,595 and \$16,082 thousand, respectively, and mainly resulted from: a \$15,558 thousand gain in the second quarter from additional consideration received from the sale of Medingo completed in 2010; a \$1,000 thousand gain in the second quarter from an increase in Jordan Valley's fair value; and a \$188 and \$701 thousand loss in the second quarter and first half of 2012, respectively, from a decrease in the Company's holding in Given Imaging as a result of options granted to Given Imaging employees having been exercised or having expired.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Financial income

Financial income in the second quarter and first half of 2013 amounted to \$193 and \$502 thousand, respectively, and resulted mainly from interest income on deposits and from translation differences.

Financial income in the second quarter and first half of 2012 amounted to \$364 and \$917 thousand, respectively, and resulted mainly from interest income on bank deposits, and from a change in the fair value of the Company's holding in GigOptix Inc. ("GigOptix") shares.

Operating expenses

Operating expenses in the second quarter and first half of 2013 amounted to \$2,520 and \$5,453 thousand, respectively, compared with \$4,085 and \$7,526 thousand, respectively, in the second quarter and first half of 2012, and comprised mainly of research and development expenses, net, selling and marketing expenses, and general and administrative expenses of Elron's, RDC's, Navitrio's and consolidated companies' corporate operations. The following table summarizes the operating expenses of Elron and its consolidated companies:

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012
	unaudited		unaudited	
	\$ thousands			
Corporate	2,034	1,998	1,042	998
RDC	880	685	486	416
Kyma	1,252	1,487	521	765
Starling (1)	-	599	-	380
Navitrio (2)	709	1,442	186	725
SmartWave	578	414	285	252
Other (3)	-	901	-	549

(1) Starling Advanced Communications Ltd. was liquidated during 2012.

(2) Includes operating expenses of Cloudyn, a subsidiary.

(3) In 2012 mainly included Sync-Rx Ltd. ("Sync-Rx", sold in November 2012).

RDC: The increase in RDC's operating expenses in the first half of 2013 compared with the first half of 2012 resulted mainly from an increase in workforce.

Navitrio: The decrease in Navitrio's operating expenses in the first half of 2013 compared with the first half of 2012 resulted mainly from a decrease in the R&D expenses of Cemmerce, an in-house project in which Navitrio ceased investment during 2013, from a decrease in Navitrio's workforce, and from a decrease in the R&D expenses of its subsidiary, Cloudyn.

SmartWave Medical Ltd. ("SmartWave"): The increase in SmartWave's operating expenses in the first half of 2013 compared with the first half of 2012 resulted mainly from an increase in research and development expenses incurred in completing the necessary actions in preparation and for the commencement of clinical trials.

Equity in losses of associates, net

Elron's share in the net losses of its associates results from its holdings in certain investments that are accounted for under the equity method. Elron's share in the net losses of its associates in the second quarter and first half of 2013 amounted to \$1,639 and \$5,213 thousand, respectively, compared with \$1,807 and \$4,991 thousand, respectively, in the second quarter and first half of 2012.

As most of the Group Companies are companies whose operations have not yet generated significant revenues, if at all, and invest considerable resources in research and development and in marketing activities, Elron expects to continue to record losses in respect of these companies' ongoing operations in accordance with the accounting method applied to them in Elron's financial statements. In addition, see the analysis of the results of operations of main associates below.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Financial expenses

Financial expenses in the second quarter and first half of 2013 amounted to \$244 and \$370 thousand, respectively, and resulted mainly from interest on the loan drawn down under the credit line agreement with Silicon Valley Bank, and from commissions and other expenses related to this credit line (see section 1.4 below).

Financial expenses in the second quarter and first half of 2012 amounted to \$1,303 and \$1,834 thousand, respectively, and resulted mainly from a change in the fair value of the Company's holding in Wave shares. (In the third quarter of 2012, the entire holding in Wave shares was sold, except for shares deposited in escrow with their receipt in the sale of Safend in September 2011).

Other expenses (income), net

Other expenses, net, in the second quarter and first half of 2012 amounted to \$500 thousand and resulted from a provision for contingent liabilities.

1.3.4. Analysis of the results of operations of main associates

Given Imaging

Given Imaging reported the following operating results (according to IFRS):

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	Increase (Decrease) %	For the three months ended June 30, 2013	For the three months ended June 30, 2012	Increase (Decrease) %
	unaudited			unaudited		
	\$ thousands			\$ thousands		
Sales	90,084	86,351	4.3%	49,464	44,512	11.1%
Operating income	5,277	3,421	54.3%	5,311	3,315	60.2%
Net income attributable to shareholders	4,918	3,793	40.8%	5,069	3,784	45.5%

The increase in Given Imaging's sales in the second quarter of 2013 compared with the second quarter of 2012 mainly resulted from an increase in sales in Given Imaging's three areas of operation. The increase in Given Imaging's sales in the first half of 2013 compared with the first half of 2012 mainly resulted from an increase in revenues in the EMEA and APAC regions. The increase in income attributable to shareholders and operating income in the second quarter and first half of 2013 compared with the second quarter and first half of 2012 mainly resulted from the increase in sales and in gross profit.

Pocared

Pocared's loss in the second quarter and first half of 2013 amounted to \$2,347 and \$4,137 thousand, respectively, compared with a loss of \$1,832 and \$3,142 thousand, respectively, in the second quarter and first half of 2012. Pocared is in the development stage and has not yet commenced sales. Pocared's losses mainly result from research and development expenses. The increase in loss was mainly due to progress in the FDA trial it is conducting.

BrainsGate

BrainsGate's loss in the second quarter and first half of 2013 amounted to \$1,075 and \$3,015 thousand, respectively, compared with a loss of \$1,889 and \$3,384 thousand, respectively, in the second quarter and first half of 2012. BrainsGate is in the development stage and has not yet commenced sales. BrainsGate's losses mainly result from research and development expenses. The decrease in loss was due to an R&D grant BrainsGate received which partially reduced R&D expenses, and from financial income BrainsGate recorded in the second quarter and first half of 2013 due to exchange rate fluctuations, as opposed to financial expenses recorded in the second quarter and first half of 2012, due to exchange rate fluctuations.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

1.4. Financial Position, Liquidity and Capital Resources

Financial position

	June 30, 2013	December 31,
	unaudited	2012
	\$ thousands	
	unaudited	audited
Total assets in the consolidated statement of financial position	188,300	197,082
Investments in associates and financial assets measured at fair value (including assets held for sale)	136,733	136,792
Other long-term receivables	833	3,832
Current assets (excluding assets classified as held for sale)	45,665	51,359
Intangible assets, net	4,922	4,922
Current liabilities	2,516	2,838
Long-term liabilities	9,555	9,325
Total liabilities	12,071	12,163
Equity including non-controlling interest	176,229	184,919

Shareholders' equity attributable to Elron's shareholders at June 30, 2013 was \$154,739 thousand, representing approximately 82% of the total assets in the statement of financial position, compared with \$162,040 thousand at December 31, 2012, representing approximately 82% of total assets in the statement of financial position.

Consolidated working capital at June 30, 2013 amounted to \$43,149 thousand, compared with \$48,521 thousand at December 31, 2012. The decrease in working capital resulted from a decrease in cash balance due to investments in Group Companies. This decrease was partially offset by the reclassification of amounts originally deposited in long-term escrow in connection with the sale of Sync-Rx as current assets.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Elron's, RDC's and Navitrio's primary cash flows (1)

	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012
	unaudited	unaudited	unaudited	unaudited
	\$ thousands			
Investments in Elron's, RDC's and Navitrio's group companies (2)	(4,308)	(6,842)	(1,846)	(2,500)
Proceeds from disposal of Elron's and RDC's non-current investments	1,994	41,398	-	40,697
Raising of Elron's debt	-	5,000	-	5,000
Repayment of RDC's loans (3)	-	(3,339)	-	(3,339)
Dividend distributed by RDC (3)	-	(8,871)	-	(8,871)

(1) The amounts presented include RDC's and Navitrio's cash flows in full (100%) in addition to Elron's cash flows, but exclude the cash flows of their subsidiaries.

(2) Excluding Elron's investment in Navitrio in the first quarter of 2013.

(3) Including Rafael's share only in the loans granted/repaid and in the dividend distributed.

Cash balance

Consolidated cash and cash equivalents at June 30, 2013 amounted to \$41,676 thousand, compared with \$47,525 thousand at December 31, 2012. Elron's and RDC's non-consolidated cash and cash equivalents at June 30, 2013 amounted to \$20,741 and \$19,357 thousand, respectively, compared with \$25,097 and \$20,267 thousand, respectively, at December 31, 2012.

Uses of cash

The main uses of cash in the second quarter and first half of 2013 were investments and loans to Group Companies in the amount of \$1,646 and \$3,308 thousand, respectively, by Elron, \$366 and \$666 thousand, respectively, by Navitrio, and \$500 thousand by RDC in the first half of 2013. Also, cash was used to pay corporate and RDC's operating expenses, as detailed above in section 1.3.3.

The main uses of cash in the second quarter and first half of 2012 were investments and loans to Group Companies in the amount of \$500 and \$4,341 thousand, respectively, by Elron, \$1,000 and \$1,500 thousand, respectively, by RDC, and \$1,000 and \$1,000 thousand, respectively, by Navitrio. Also, cash was used to pay corporate and RDC's operating expenses, as detailed above in section 1.3.3. In addition, RDC's cash was used to prepay its entire debt to its shareholders in the amount of \$6,500 thousand, of which Elron's share amounted to \$3,250 thousand (approximately \$3,300 thousand including interest), and to distribute a cash dividend to its shareholders in the amount of approximately \$17,800 thousand, of which Elron's share amounted to approximately \$8,900 thousand.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Investments in Group Companies during the first half of 2013 and 2012 are summarized in the following table (see also Note 3 to the Financial Statements for additional details regarding investments in Group Companies):

	Elron		RDC		Navitrio	
			For the six months ended June 30,			
	2013	2012	2013	2012	2013	2012
			unaudited			
			\$ thousands			
Consolidated Companies (1)						
Kyma	-	-	-	1,500	-	-
SmartWave	-	-	500	-	-	-
Cloudyn (2)	-	-	-	-	666	500
	-	-	500	1,500	666	500
Associates and Other Investments						
Pocared	3,008	-	-	-	-	-
NuLens	300	1,477	-	-	-	-
BrainsGate	-	2,364	-	-	-	-
Numbeez (2)	-	-	-	-	-	500
Notal Vision (3)	-	500	-	-	-	-
	3,308	4,341	-	-	-	500
Total investments	3,308	4,341	500	1,500	666	1,000

(1) The amounts exclude Elron's investment in Navitrio in the amount of \$1,000 thousand in the first half of 2013 and RDC's investment in Navitrio in the amount of \$1,000 thousand in July 2013, subsequent to the date of this report. These investments do not affect the cash included in the Financial Statements.

(2) Subsequent to the date of this report Navitrio invested \$400 thousand in Pose, \$100 thousand in Numbeez, and \$100 thousand in Cloudyn.

(3) Subsequent to the date of this report Elron invested approximately \$970 thousand in Notal Vision.

Proceeds from the disposal of Elron's and RDC's non-current investments

Proceeds Elron and RDC received from the disposal of non-current investments in the first half of 2013 mainly included proceeds Elron received in the amount of \$1,923 thousand from its share in the release of the deposit that was held in escrow in connection with the sale of Wavion Inc. ("Wavion") that was completed in 2011.

Proceeds Elron and RDC received from the disposal of non-current investments in the first half of 2012 mainly included: proceeds Elron and RDC received in the second quarter in the amount of approximately \$1,409 and \$14,149 thousand, respectively, from the sale of Medingo completed in 2010; proceeds Elron and RDC received in the second quarter in the amount of approximately \$2,702 and \$19,908 thousand, respectively, from the release of the deposit that was held in escrow in connection with the sale of Medingo; proceeds Elron received in the second quarter in the amount of \$1,272 thousand from the sale of Wavion completed in November 2011; proceeds Elron received in the second quarter in the amount of \$871 thousand from the sale of Wave shares; and proceeds Elron received in the first half in the amount of \$837 thousand from the sale of the remainder of its holding in GigOptix shares.

Credit line extension

In April 2013, Elron and Silicon Valley Bank ("SVB") entered into a credit line extension agreement. The previous credit line in the amount of \$30,000 was available until May 2013, of which \$5,000 thousand were utilized. In August 2012, Elron prepaid \$1,000 thousand out of this debt, and as of the date of this report, Elron has an outstanding debt to SVB in the amount of \$4,000 thousand in respect of the previous credit line. The terms of the previous credit line continue to apply to the outstanding debt, and are detailed in Note 11 to Elron's consolidated financial statements as of December 31, 2012. The credit line was extended in order to ensure and diversify additional sources of financing towards continued investing in the Group Companies and in new companies and to finance Elron's ongoing operations, and due to the partial utilization of the previous credit line which was about to expire.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

The terms of the credit line extension agreement are detailed below:

Credit Amount-	\$25,000 thousand.
Draw Period-	\$10,000 thousand are available from the signing of the agreement until December 31, 2013. An additional \$15,000 thousand are available from the signing of the agreement until October 30, 2014.
Repayment date-	24 months after each respective draw.
Prepayment-	Elron will be entitled to make prepayment without any cost at any time.
Repayment upon Exit Transaction-	If Elron receives aggregate proceeds greater than \$30,000 thousand from the sale of a Group Company ("Exit Transaction"), SVB will have the right to demand repayment in an amount equal to 50% of the proceeds received in cash (not exceeding the amount of the outstanding debt).
Dividend Distribution-	If Elron distributes a dividend, SVB will have the right to demand repayment in an amount equal to 100% of the dividend (not exceeding the amount of the outstanding debt). Notwithstanding, should prepayment be made following an Exit Transaction or at Elron's initiative, SVB will not have the right to additional prepayment in the event Elron distributes a dividend up to the amount that was prepaid.
Interest-	Wall Street Journal Prime rate plus 1.75% per annum.
Unused Line Fee-	0.5% per annum of the unused portion of the credit amount.
Collateral-	At the time the credit line is actually utilized, Elron will pledge shares directly held by it in Given Imaging in an amount equal to maintain a 3.25 ratio of the market value of the pledged shares (based on their trailing 5-day average closing price prior to the computation date) to the amount of credit utilized. Should the coverage ratio of the market value of the pledged shares to the credit amount utilized decrease below 3, then Elron shall either pledge additional Given Imaging shares or repay a portion of the credit utilized in order to maintain a coverage ratio of 3.25, or provide alternative collateral acceptable to SVB. As of the date of this report, Elron has pledged 1,130,000 shares of Given Imaging in favor of SVB pursuant to the terms of the previous credit line, representing, as of June 30, 2013, approximately 3.6% of Given Imaging's outstanding shares. As of June 30, 2013 the coverage ratio is approximately 3.9, and as of August 12, 2013, the coverage ratio is approximately 4.6.

At June 30, 2013, Elron had a \$4,000 thousand debt to banks. RDC had no debt at June 30, 2013.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Main Group Companies' cash flows

	Cash flows from operating activities				Cash balance		Note in Financial Statements
	For the six months ended June 30, 2013	For the six months ended June 30, 2012	For the three months ended June 30, 2013	For the three months ended June 30, 2012	As of June 30, 2013	As of December 31, 2012	
	Unaudited				Audited		
	\$ thousands						
BrainsGate	(3,013)	(3,122)	(1,467)	(1,554)	12,313	8,707	-
Given Imaging	6,612	7,583	8,834	6,909	30,633	35,442	-
Pocared	(3,934)	(2,788)	(2,124)	(1,242)	4,533	2,047	3.A

2. Market Risk Exposure and Management

The report in this section refers to Elron and its consolidated companies to the extent that the exposure to market risks is material. The Company's risk management policy is implemented only for Elron itself. Elron does not determine the risk management policy for its Group Companies, and has not taken any action in the period of this report to hedge market risks resulting from operations of its Group Companies. During the period of this report, and during the period from June 30, 2013 until the date of filing this report, no material change has taken place with respect to the market risks to which the Company is exposed, the Company's policy for managing such risks, the officer responsible for their management and the means of supervising and implementing the policy, as described in Item 5 of Elron's 2012 Annual Report.

2.1. Report on Linkage Bases

Presented below is the Company's consolidated linkage balance at June 30, 2013, December 31, 2012, and June 30, 2012.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

As of June 30, 2013 (\$ thousands) (unaudited)

	NIS (CPI linked)	USD (or USD linked)	NIS (unlinked)	Non- monetary item (2)	Total
Assets (1)					
Cash and cash equivalents	-	31,917	9,759	-	41,676
Other account receivables	50	245	376	250	921
Investments in associates	-	-	-	113,110	113,110
Other investments measured at fair value	-	-	-	23,623	23,623
Property, plant and equipment, net	-	-	-	147	147
Intangible assets, net	-	-	-	4,922	4,922
Other long-term receivables	-	3,758	68	75	3,901
	<u>50</u>	<u>35,920</u>	<u>10,203</u>	<u>142,127</u>	<u>188,300</u>
Liabilities (1)					
Trade payables	1	27	138	-	166
Other account payables	-	623	1,439	288	2,350
Loans from banks and others	-	4,000	-	-	4,000
Royalty bearing government grants	-	955	-	-	955
Employee benefits, net	-	-	-	4	4
Long-term taxes	-	-	-	4,596	4,596
	<u>1</u>	<u>5,605</u>	<u>1,577</u>	<u>4,888</u>	<u>12,071</u>

(1) Non-current assets and liabilities in this table include the current maturities in respect thereof.

(2) Including items that are not financial items.

As of December 31, 2012 (\$ thousands) (audited)

	NIS (CPI linked)	USD (or USD linked)	NIS (unlinked)	Non- monetary item (2)	Total
Assets (1)					
Cash and cash equivalents	-	44,766	2,759	-	47,525
Other account receivables	34	1,443	91	296	1,864
Investments in associates	-	-	-	113,217	113,217
Other investments measured at fair value	-	-	-	23,575	23,575
Property, plant and equipment, net	-	-	-	177	177
Intangible assets, net	-	-	-	4,922	4,922
Other long-term receivables	-	5,663	64	75	5,802
	<u>34</u>	<u>51,872</u>	<u>2,914</u>	<u>142,262</u>	<u>197,082</u>
Liabilities (1)					
Trade payables	11	49	177	-	237
Other account payables	-	944	1,348	309	2,601
Loans from banks and others	-	4,000	-	-	4,000
Royalty bearing government grants	-	864	-	-	864
Employee benefits, net	-	-	-	4	4
Long-term taxes	-	-	-	4,457	4,457
	<u>11</u>	<u>5,857</u>	<u>1,525</u>	<u>4,770</u>	<u>12,163</u>

(1) Non-current assets and liabilities in this table include the current maturities in respect thereof.

(2) Including items that are not financial items.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

As of June 30, 2012 (\$ thousands) (unaudited)

	NIS (CPI linked)	USD (or USD linked)	NIS (unlinked)	Non- monetary item (2)	Total
Assets (1)					
Cash and cash equivalents	-	57,332	5,629	-	62,961
Other account receivables	86	263	572	326	1,247
Assets held for sale	-	-	-	651	651
Investments in associates	-	-	-	109,296	109,296
Other investments measured at fair value	-	-	-	17,924	17,924
Property, plant and equipment, net	-	-	-	224	224
Intangible assets, net	-	-	-	4,922	4,922
Other long-term receivables	-	5,290	64	-	5,354
Total assets	86	62,885	6,265	133,343	202,579
Liabilities (1)					
Trade payables	-	34	531	-	565
Other account payables	-	16,658	2,589	328	19,575
Loans from banks and others	-	5,000	-	-	5,000
Royalty bearing government grants	-	1,634	-	-	1,634
Employee benefits, net	-	-	-	5	5
Long-term taxes	-	-	-	4,743	4,743
Total liabilities	-	23,326	3,120	5,076	31,522

(1) Non-current assets and liabilities in this table include the current maturities in respect thereof.

(2) Including items that are not financial items.

2.2. Sensitivity Tests of Financial Instruments

The following tables describe sensitivity tests of the fair value of financial instruments included in the Financial Statements that are held by the Company and its subsidiaries, in accordance with changes in market factors.

The following comments should be considered with regards to the tables below:

1. The instruments that appear below are not necessarily presented in the Financial Statements at fair value.
2. The exchange rates according to which the sensitivity tests were carried out are the closing rates on the day of calculation.
3. Sensitivity tests for the influence of interest rate changes on financial assets and financial liabilities were not presented due to their negligible influence on their fair value.

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

I. Sensitivity tests of balances as of June 30, 2013

Sensitivity test of changes in the dollar-NIS exchange rate

Section	Fair value	Gain (loss) from changes in the dollar-NIS exchange rate			
		Increase		Decrease	
		10%	5%	10%	5%
		\$ thousands			
Current Assets:					
Other account receivables	426	43	21	(43)	(21)
Cash and cash equivalents	9,759	976	488	(976)	(488)
Non-current assets:					
Long-term receivables	68	7	3	(7)	(3)
Current liabilities:					
Trade payables and other account payables	(1,578)	(158)	(79)	158	79
	<u>8,675</u>	<u>868</u>	<u>433</u>	<u>(868)</u>	<u>(433)</u>

Sensitivity test of changes in share prices of other investments measured at fair value

Section	Fair value	Gain (loss) from changes in the price of shares			
		Increase		Decrease	
		10%	5%	10%	5%
		\$ thousands			
Other investments measured at fair value	23,623	2,362	1,181	(2,362)	(1,181)

II. Sensitivity tests of balances as of December 31, 2012

Sensitivity test of changes in the dollar-NIS exchange rate

Section	Fair value	Gain (loss) from changes in the dollar-NIS exchange rate			
		Increase		Decrease	
		10%	5%	10%	5%
		\$ thousands			
Current Assets:					
Other account receivables	126	13	6	(13)	(6)
Cash and cash equivalents	2,759	276	138	(276)	(138)
Non-current assets:					
Long-term receivables	980	98	49	(98)	(49)
Current liabilities:					
Trade payables and other account payables	(1,528)	(153)	(76)	153	76
	<u>2,337</u>	<u>234</u>	<u>117</u>	<u>(234)</u>	<u>(117)</u>

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Sensitivity test of changes in share prices of other investments measured at fair value

Section	Fair value	Gain (loss) from changes in the price of shares			
		Increase		Decrease	
		10%	5%	10%	5%
Other investments measured at fair value	23,575	2,358	1,179	(2,358)	(1,179)

III. Sensitivity tests of balances as of June 30, 2012

Sensitivity test of changes in dollar interest rates

Section	Fair value	Gain (loss) from changes in dollar interest rates					
		Increase			Decrease		
		2% Absolute value	10%	5%	2% Absolute value	10%	5%
Other long-term receivables	2,720	(131)	(57)	(29)	140	58	29

Sensitivity test of changes in the dollar-NIS exchange rate

Section	Fair value	Gain (loss) from changes in the dollar-NIS exchange rate			
		Increase		Decrease	
		10%	5%	10%	5%
Current Assets:					
Other account receivables	642	64	32	(64)	(32)
Cash and cash equivalents	4,590	459	230	(459)	(230)
Non-current assets:					
Long-term receivables	44	4	2	(4)	(2)
Current liabilities:					
Trade payables and other account payables	(3,046)	(305)	(152)	305	152
	2,230	223	112	(223)	(112)

Elron Electronic Industries Ltd.
Part II
English Translation of Board of Directors Report
for the Second Quarter of 2013

Sensitivity test of changes in share prices of other investments (accounted for as available for sale)

Section	Fair value	Gain (loss) from changes in the price of shares			
		Increase		Decrease	
		10%	5%	10%	5%
		\$ thousands			
Other investments measured at fair value	17,924	1,792	896	(1,792)	(896)
Assets classified as held for sale	130	13	7	(13)	(7)
	18,054	1,805	903	(1,805)	(903)

Arie Mientkavich
Chairman

Ari Bronshtein
CEO

August 13, 2013, Tel Aviv

Elron Electronic Industries Ltd.

Part III

**English Translation of Interim
Consolidated Financial Statements**

**As of
June 30, 2013
Unaudited**

Interim Consolidated Financial Statements as of June 30, 2013

	<u>Page</u>
Auditors' Review Report	F - 2
Consolidated Statements of Financial Position	F - 3- F - 4
Consolidated Statements of Income	F - 5
Consolidated Statements of Comprehensive Income	F - 6
Consolidated Statements of Changes in Equity	F - 7 - F - 11
Consolidated Statements of Cash Flows	F - 12 - F - 13
Notes to the Interim Consolidated Financial Statements	F - 14 - F - 26
Annex to the Interim Consolidated Financial Statements - Details regarding investments in the consolidated financial statements as of June 30, 2013	F - 27

Auditors' review report to the shareholders of
Elron Electronic Industries Ltd.

Introduction

We have reviewed the accompanying financial information of Elron Electronic Industries Ltd. and its subsidiaries ("the Group"), which comprises the condensed consolidated balance sheet as of June 30, 2013 and the related condensed consolidated statements of income, comprehensive income, changes in equity and cash flows for the six and three months then ended. The Company's board of directors and management are responsible for the preparation and presentation of interim financial information for these periods in accordance with IAS 34, "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review.

We did not review the condensed interim financial information of certain associate, the investment in which, at equity, amounted to approximately \$61 million as of June 30, 2013, and the Company's share in its earnings amounted to approximately \$1,483 thousand and \$1,529 thousand for the six and three months then ended, respectively. The condensed interim financial information of this company was reviewed by other auditors, whose review reports have been furnished to us, and our conclusion, insofar as it relates to the financial information in respect of this company, is based on the review reports of the other auditors.

Scope of review

We conducted our review in accordance with Review Standard 1 of the Institute of Certified Public Accountants in Israel, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards in Israel and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review and the review reports of other auditors, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34.

In addition to the abovementioned, based on our review and the review reports of other auditors, nothing has come to our attention that causes us to believe that the accompanying interim financial information does not comply, in all material respects, with the disclosure requirements of Chapter D of the Securities Regulations (Periodic and Immediate Reports), 1970.

Tel-Aviv, Israel
August 13, 2013

KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global

Consolidated Statements of Financial Position

	June 30		December 31
	2013	2012	2012
	Unaudited		Audited
	\$ thousands		
Current assets			
Cash and cash equivalents	41,676	62,961	47,525
Other accounts receivable	3,989	3,198	3,834
	<u>45,665</u>	<u>66,159</u>	<u>51,359</u>
Assets held for sale	-	651	-
Non-current assets			
Investments in associates	113,110	109,296	113,217
Other investments measured at fair value	23,623	17,924	23,575
Other long-term receivables	833	3,403	3,832
Property, plant and equipment, net	147	224	177
Intangible assets, net	4,922	4,922	4,922
	<u>142,635</u>	<u>135,769</u>	<u>145,723</u>
Total assets	<u>188,300</u>	<u>202,579</u>	<u>197,082</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Financial Position

	June 30		December 31
	2013	2012	2012
	Unaudited		Audited
	\$ thousands		
Current liabilities			
Trade payables	166	565	237
Other accounts payable	2,350	4,585	2,601
Dividend payables	-	15,000	-
	<u>2,516</u>	<u>20,150</u>	<u>2,838</u>
Long-term liabilities			
Long term loans from banks and others	4,000	5,000	4,000
Royalty bearing government grants	955	1,624	864
Employee benefits	4	5	4
Long term taxes	4,596	4,743	4,457
	<u>9,555</u>	<u>11,372</u>	<u>9,325</u>
Equity attributable to the Company's shareholders			
Issued capital	9,573	9,573	9,573
Share premium	190,753	190,378	190,709
Capital reserves	(9,580)	(10,039)	(9,868)
Accumulated deficit	(36,007)	(35,970)	(28,374)
	<u>154,739</u>	<u>153,942</u>	<u>162,040</u>
Non-controlling interests			
	<u>21,490</u>	<u>17,115</u>	<u>22,879</u>
Total equity	<u>176,229</u>	<u>171,057</u>	<u>184,919</u>
Total liabilities and equity	<u>188,300</u>	<u>202,579</u>	<u>197,082</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

August 13, 2013

Date of approval of the
financial statements

Arie Mientkavich
Chairman of the Board of Directors

Ari Bronshtein
Chief Executive Officer

Yaron Elad
Vice President &
Chief Financial Officer

Consolidated Statements of Income

	Six months ended June 30		Three months ended June 30		Year ended December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
	(except for income (loss) per share data)				
Income					
Gain from disposal and revaluation of investee companies and changes in holdings, net	2,268	16,082	1,921	16,595	39,426
Financial income	502	917	193	364	1,241
	2,770	16,999	2,114	16,959	40,667
Expenses					
Research and development expenses, net	2,283	3,129	987	1,697	6,869
Selling and marketing expenses	218	264	70	155	905
General and administrative expenses	2,952	4,133	1,463	2,233	7,190
Equity in losses of associates, net	5,213	4,991	1,639	1,807	8,357
Financial expenses	370	1,834	244	1,303	2,052
Other expenses (income), net	17	500	12	500	(282)
	11,053	14,851	4,415	7,695	25,091
Income (loss) before taxes on income	(8,283)	2,148	(2,301)	9,264	15,576
Tax benefit	-	161	-	161	262
Net income (loss)	(8,283)	2,309	(2,301)	9,425	15,838
Attributable to:					
The Company's shareholders	(7,633)	(3,098)	(2,171)	3,120	4,357
Non-controlling interests	(650)	5,407	(130)	6,305	11,481
	(8,283)	2,309	(2,301)	9,425	15,838
Net income (loss) per share attributable to the Company's shareholders (in \$):					
Basic and diluted net income (loss) per share	(0.29)	(0.13)	(0.09)	0.09	0.09

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Comprehensive Income

	Six months ended June 30		Three months ended June 30		Year ended December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
Net income (loss)	(8,283)	2,309	(2,301)	9,425	15,838
Other comprehensive loss (net of tax):					
Amounts that would never be reclassified to profit or loss:					
Loss from financial assets measured at fair value through other comprehensive income, net	(429)	(1,333)	(107)	(1,086)	(1,313)
Group's share of other comprehensive income, net, of companies accounted for under the equity method	-	-	-	-	164
Total loss that would never be reclassified to profit or loss	(429)	(1,333)	(107)	(1,086)	(1,149)
Amounts that are classified or may be reclassified to profit or loss under certain conditions:					
Foreign currency translation differences of foreign operations	-	(53)	-	(139)	(54)
Foreign currency translation differences charged to the statement of income upon disposal of foreign operations	-	-	-	-	80
Total gain (loss) that would be reclassified to profit or loss	-	(53)	-	(139)	26
Total other comprehensive loss	(429)	(1,386)	(107)	(1,225)	(1,123)
Total comprehensive income (loss)	(8,712)	923	(2,408)	8,200	14,715
Attributable to:					
Company's shareholders	(8,062)	(4,481)	(2,278)	1,905	3,214
Non-controlling interests	(650)	5,404	(130)	6,295	11,501
	(8,712)	923	(2,408)	8,200	14,715

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Changes in Equity

	Attributable to the Company's shareholders									
	Issued capital	Share Premium	Capital reserve for transaction with controlling interests	Capital reserve for financial assets measured at fair value through other comprehensive income	Capital reserve from transactions with non-controlling interests	Accumulated deficit from share based payments	Accumulated deficit	Total	Non-controlling interests	Total equity
	Unaudited									
	\$ thousands									
Balance at January 1, 2013 (Audited)	9,573	190,709	351	(11,326)	1,107	391	(28,765)	162,040	22,879	184,919
Total comprehensive loss	-	-	-	(429)	-	-	(7,633)	(8,062)	(650)	(8,712)
Share-based payments in respect of awards issued by subsidiaries	-	-	-	-	-	-	-	-	(22)	(22)
Change in non-controlling interests in consolidated company	-	-	-	-	717	-	-	717	(717)	-
Expiration of share-based payments	-	-	-	-	-	(379)	379	-	-	-
Exercise of options into shares of the Company	*)	44	-	-	-	(12)	12	44	-	44
Balance at June 30, 2013	9,573	190,753	351	(11,755)	1,824	-	(36,007)	154,739	21,490	176,229

*) Amount less than \$1 thousand.

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Changes in Equity

	Attributable to the Company's shareholders										
	Issued capital	Share Premium	Capital reserve for transaction with controlling interests	Capital reserve for financial assets measured at fair value through other comprehensive income	Capital reserve from translation differences	Capital reserve from transactions with non-controlling interests	Accumulated deficit from share based payments	Accumulated deficit	Total	Non-controlling interests	Total equity
	Unaudited										
	\$ thousands										
Balance at January 1, 2012											
(Audited)	9,573	190,378	351	(10,013)	(29)	1,221	1,175	(19,047)	173,609	20,474	194,083
Total comprehensive income (loss)	-	-	-	(1,333)	(50)	-	-	(3,098)	(4,481)	5,404	923
Share-based payments in respect of awards issued by subsidiaries	-	-	-	-	-	-	-	-	-	336	336
Expiration of share-based payment instruments	-	-	-	-	-	-	(695)	695	-	-	-
Purchase of shares of subsidiary from non-controlling interests	-	-	-	-	-	(303)	-	-	(303)	(111)	(414)
Investment in subsidiary by RDC	-	-	-	-	-	117	-	-	117	(117)	-
Dividend to equity holders of the Company	-	-	-	-	-	-	-	(15,000)	(15,000)	-	(15,000)
Dividend paid by a subsidiary to non-controlling interests	-	-	-	-	-	-	-	-	-	(8,871)	(8,871)
Balance at June 30, 2012	<u>9,573</u>	<u>190,378</u>	<u>351</u>	<u>(11,346)</u>	<u>(79)</u>	<u>1,035</u>	<u>480</u>	<u>(36,450)</u>	<u>153,942</u>	<u>17,115</u>	<u>171,057</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Changes in Equity

	Attributable to the Company's shareholders							Non-controlling interests	Total equity
	Issued capital	Share Premium	Capital reserve for transaction with controlling interests	Capital reserve for financial assets measured at fair value through other comprehensive income	Capital reserve from transactions with non-controlling interests	Accumulated deficit	Total		
	Unaudited								
	\$ thousands								
Balance at April 1, 2013	9,573	190,753	351	(11,648)	1,107	(33,836)	156,300	22,431	178,731
Total comprehensive loss	-	-	-	(107)	-	(2,171)	(2,278)	(130)	(2,408)
Share-based payments in respect of awards issued by subsidiaries	-	-	-	-	-	-	-	(94)	(94)
Change in non-controlling interests in consolidated company	-	-	-	-	717	-	717	(717)	-
Balance at June 30, 2013	<u>9,573</u>	<u>190,753</u>	<u>351</u>	<u>(11,755)</u>	<u>1,824</u>	<u>(36,007)</u>	<u>154,739</u>	<u>21,490</u>	<u>176,229</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Changes in Equity

	Attributable to the Company's shareholders										
	Issued capital	Share Premium	Capital reserve for transaction with controlling interests	Capital reserve for financial assets measured at fair value through other comprehensive income	Capital reserve from translation differences	Capital reserve from transactions with non-controlling interests	Accumulated deficit from share based payments	Accumulated deficit	Total	Non-controlling interests	Total equity
	Unaudited										
	\$ thousands										
Balance at April 1, 2012	9,573	190,378	351	(10,260)	50	1,221	1,175	(25,265)	167,223	19,771	186,994
Total comprehensive income (loss)	-	-	-	(1,086)	(129)	-	-	3,120	1,905	6,295	8,200
Share-based payments in respect of awards issued by subsidiaries	-	-	-	-	-	-	-	-	-	148	148
Expiration of share-based payment instruments	-	-	-	-	-	-	(695)	695	-	-	-
Purchase of shares of subsidiary from non-controlling interests	-	-	-	-	-	(303)	-	-	(303)	(111)	(414)
Investment in subsidiary by RDC	-	-	-	-	-	117	-	-	117	(117)	-
Dividend to equity holders of the Company	-	-	-	-	-	-	-	(15,000)	(15,000)	-	(15,000)
Dividend paid by a subsidiary to non-controlling interests	-	-	-	-	-	-	-	-	-	(8,871)	(8,871)
Balance at June 30, 2012	<u>9,573</u>	<u>190,378</u>	<u>351</u>	<u>(11,346)</u>	<u>(79)</u>	<u>1,035</u>	<u>480</u>	<u>(36,450)</u>	<u>153,942</u>	<u>17,115</u>	<u>171,057</u>

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Changes in Equity

	Attributable to the Company's shareholders										
	Issued capital	Share premium	Capital reserve for transaction with controlling interests	Capital reserve for financial assets measured at fair value through other comprehensive income	Capital reserve from translation differences	Capital reserve from transactions with non-controlling interests	Accumulated deficit from share based payments	Accumulated deficit	Total	Non-controlling interests	Total equity
	Audited										
	\$ thousands										
Balance at January 1, 2012	9,573	190,378	351	(10,013)	(29)	1,221	1,175	(19,047)	173,609	20,474	194,083
Total comprehensive income (loss)	-	-	-	(1,313)	29	-	-	4,498	3,214	11,501	14,715
Share-based payments in respect of awards issued by subsidiaries	-	-	-	-	-	-	-	-	-	492	492
Exercise of options into shares in a subsidiary	-	-	-	-	-	11	-	-	11	11	22
Expiration of share-based payments	-	-	-	-	-	-	(695)	695	-	-	-
Exercise of options into shares of the Company	-*)	331	-	-	-	-	(89)	89	331	-	331
Purchase of shares of subsidiary from non-controlling interests	-	-	-	-	-	(303)	-	-	(303)	(111)	(414)
Dividend to equity holders of the Company	-	-	-	-	-	-	-	(15,000)	(15,000)	-	(15,000)
Dividend paid by a subsidiary to non-controlling interests	-	-	-	-	-	-	-	-	-	(8,871)	(8,871)
Change in non-controlling interests due to sale of a subsidiary	-	-	-	-	-	-	-	-	-	(439)	(439)
Investment in subsidiary by RDC	-	-	-	-	-	178	-	-	178	(178)	-
Balance at December 31, 2012	<u>9,573</u>	<u>190,709</u>	<u>351</u>	<u>(11,326)</u>	<u>-</u>	<u>1,107</u>	<u>391</u>	<u>(28,765)</u>	<u>162,040</u>	<u>22,879</u>	<u>184,919</u>

*) Amount less than \$1 thousand.

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Cash Flows

	Six months ended June 30		Three months ended June 30		Year ended December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
Cash flows from operating activities					
Net income (loss)	(8,283)	2,309	(2,301)	9,425	15,838
Adjustments to reconcile net income (loss) to net cash used in operating activities:					
Adjustment to the profit or loss items:					
Depreciation and amortization	47	45	31	23	83
Financial expenses (income), net	(376)	(65)	(123)	72	(299)
Stock based compensation and changes in liability in respect of options	(43)	320	(105)	139	454
Change in fair value of financial assets measured at fair value	-	1,317	-	1,185	1,407
Gain from disposal and revaluation of investee companies and changes in holdings, net	(2,268)	(16,082)	(1,921)	(16,595)	(39,426)
Equity in losses of associates, net	5,213	4,991	1,639	1,807	8,357
Tax benefit	-	(161)	-	(161)	(262)
Other	(66)	(284)	(31)	(340)	(485)
	2,507	(9,919)	(510)	(13,870)	(30,171)
Changes in Assets and Liabilities:					
Decrease (increase) in other accounts receivable	86	384	(170)	(294)	449
Decrease in inventories	-	99	-	-	99
Increase (decrease) in liabilities in respect of government grants	14	(257)	2	58	(507)
Increase (decrease) in trade payables	(71)	(91)	12	(229)	(165)
Increase (decrease) in other accounts payable	(230)	28	(493)	882	(1,306)
	(201)	163	(649)	417	(1,430)
Cash paid and received during the year for:					
Taxes paid	-	-	-	-	(2,170)
Taxes received	-	-	-	-	1,734
Interest paid	(83)	(89)	(43)	(89)	(174)
Interest received	148	154	61	17	473
	65	65	18	(72)	(137)
Net cash used in operating activities	(5,912)	(7,382)	(3,442)	(4,100)	(15,900)

The accompanying notes are an integral part of the interim consolidated financial statements.

Consolidated Statements of Cash Flow (Cont.)

	Six months ended		Three months ended		Year ended
	June 30		June 30		December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
Cash flows from investment activities					
Purchase of property and equipment	(17)	(23)	(14)	(6)	(57)
Investment in associates and other companies	(3,308)	(4,341)	(1,646)	(500)	(12,230)
Proceeds from sale of property and equipment	-	-	-	-	6
Proceeds from sale of investments in subsidiaries net of cash disposed of due to deconsolidation	1,970	39,440	-	39,440	51,651
Proceeds from sale of Starling's operation	-	-	-	-	2,745
Proceeds from sale of associates and other companies	23	250	-	171	2,218
Proceeds from sale of financial assets measured at fair value	-	1,708	-	1,086	1,748
Long term deposits, net	930	(472)	-	(472)	(930)
Net cash provided by (used in) investment activities	(402)	36,562	(1,660)	39,719	45,151
Cash flows from financing activities					
Receipt of government grants	110	1,050	110	195	1,291
Proceeds from exercise of options	44	-	-	-	331
Investment of non-controlling interests in subsidiaries	-	-	-	-	22
Dividend paid to the Company's shareholders	-	-	-	-	(15,000)
Dividend paid to non-controlling interests	-	(8,871)	-	(8,871)	(8,871)
Purchase of shares and options from non-controlling interests	-	(414)	-	(414)	(414)
Receipt of long-term loans from banks and others	-	5,000	-	5,000	5,000
Repayment of other long-term loans and liabilities	-	(3,339)	-	(3,339)	(4,339)
Net cash provided by (used in) financing activities	154	(6,574)	110	(7,429)	(21,980)
Exchange rate differences in respect of cash and cash equivalents	311	293	105	91	192
Increase (decrease) in cash and cash equivalents	(5,849)	22,899	(4,887)	28,281	7,463
Cash and cash equivalents as of beginning of the period	47,525	40,062	46,563	34,680	40,062
Cash and cash equivalents as of end of the period	41,676	62,961	41,676	62,961	47,525

The accompanying notes are an integral part of the interim consolidated financial statements.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 1 – General

Elron Electronic Industries Ltd. ("Elron" or "the Company") is a high technology operational holding company with holdings in private and public companies in various technology fields such as medical devices and other fields. The Company is an Israeli-resident company incorporated in Israel, traded on the Tel-Aviv Stock Exchange, its main trade market, and the Over-The-Counter market in the United States. Its registered address is 3 Azrieli Center, Triangle Tower, 42nd floor, Tel Aviv.

The Company's controlling shareholder is Discount Investment Corporation Ltd. ("DIC"), an Israeli-resident company, traded on the Tel-Aviv Stock Exchange. DIC holds an approximately 50.32% interest in the Company as of June 30, 2013.

The accompanying consolidated financial statements have been prepared as of June 30, 2013, and for the six and three months then ended ("interim consolidated financial statements") in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") in condensed format. The interim consolidated financial statements are presented in U.S. dollars, the Company's functional currency, and are rounded to the nearest thousand. These interim consolidated financial statements should be read in conjunction with the Company's annual consolidated financial statements as of December 31, 2012 and the year then ended and accompanying notes ("the annual consolidated financial statements").

Note 2 – Significant Accounting Policies**A. Basis of presentation**

The interim consolidated financial statements were prepared in accordance with generally accepted accounting policies for the preparation of financial statements for interim periods as prescribed in IAS 34 – Interim Financial Reporting, and in accordance with Section D of the Israeli Securities Regulations (Periodic and Immediate Reports), 1970.

The significant accounting policies followed in the preparation of the interim consolidated financial statements are identical to those applied in preparation of the annual consolidated financial statements, with the exception of the following:

IAS 1 - Presentation of Financial Statements

In June 2011, the IASB issued an amendment to IAS 1, regarding presentation of items of Other Comprehensive Income ("OCI"). According to the amendment items of OCI that may be reclassified to profit or loss in the future, would be presented separately from those that would never be reclassified to profit or loss.

The amendment is effective for annual periods beginning on or after January 1, 2013. The amendment is applied retrospectively. The necessary disclosures are included in the Company's consolidated financial statements once applicable.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 2 – Significant Accounting Policies (Cont.)**IFRS 13 - Fair Value Measurement**

In May 2011 the IASB issued IFRS 13 ("IFRS 13"). IFRS 13 replaces the fair value measurement guidance contained in individual IFRSs with a single source of fair value measurement guidance. It defines fair value, establishes a framework for measuring fair value and sets out disclosure requirements for fair value measurements. IFRS 13 does not introduce new requirements to measure assets or liabilities at fair value. IFRS 13 is applicable prospectively for annual periods beginning on or after January 1, 2013. The disclosure requirements of IFRS 13 need not be applied in comparative information for periods before initial application. The application of this standard did not have any material impact on the Company's consolidated financial statements.

B. Budget Law

On July 30, 2013, the Israeli Parliament (the Knesset) approved the second and third readings of the Economic Plan for 2013-2014 ("Amended Budget Law") which consists, among others, of fiscal changes whose main aim is to enhance long-term collection of taxes.

These changes include, among others, raising the Israeli corporate tax rate from 25% to 26.5%, cancelling the lowering of the tax rates applicable to preferred enterprises (9% in development area A and 16% in other areas), taxing revaluation gains and increasing the tax rates on dividends within the scope of the Law for the Encouragement of Capital Investments to 20% effective from January 1, 2014.

The Company estimates that the effect of the change in tax rates will lead to a change in tax balances as of June 30, 2013 in immaterial amounts, if any.

Note 3 – Material Changes During the Reporting Period**A. Pocared**

Pocared Diagnostics Ltd. ("Pocared"), an Israeli company, is developing a real-time and automated system for infectious diseases diagnosis using optical technology. As of the reporting date, Elron holds approximately 41% of Pocared's outstanding shares and Pocared is accounted for under the equity method of accounting.

As mentioned in Note 3.C.1.a) to the annual consolidated financial statements, in January 2011, Pocared signed an investment agreement with its major shareholders, including Elron, whereby a total amount of approximately \$17,000 was advanced in four equal installments in consideration for Preferred F shares. During 2011, three installments were advanced to Pocared in an aggregate amount of approximately \$13,300. Elron's share in these installments was approximately \$6,000. In January 2013, the fourth and last installment was advanced to Pocared in the amount of approximately \$3,700. Elron's share in this installment was approximately \$1,700.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 3 – Material Changes During the Reporting Period (Cont.)

In May 2013, Pocared signed an investment agreement with its major shareholders, including Elron, whereby a total amount of up to \$10,000 will be advanced in two installments in consideration for additional Preferred F shares. The first installment in respect of this investment in the amount of approximately \$3,000 was advanced in the same month. Elron's share in this installment was approximately \$1,400. The second installment will be advanced conditionally upon Pocared achieving a certain milestone as stipulated in the agreement. Elron's holding in Pocared is not expected to significantly change as a result from this investment agreement.

B. Wavion

Wavion Inc. ("Wavion") provides outdoor Wi-Fi base station solutions which provide increased coverage and capacity, enhanced penetration, and immunity to interference as compared with conventional Wi-Fi access points. Prior to its sale, Elron directly held approximately 67% of Wavion's outstanding shares.

As mentioned in Note 3.C.2.g) to the annual consolidated financial statements, in November 2011, the sale of all of the shares of Wavion to Alvarion Ltd. was completed. According to the sale agreement, an amount of approximately \$1,900 was deposited in escrow.

In February 2013, the Company received the escrow deposit in the amount of approximately \$1,900. This amount was recognized in 2011 as a gain from disposal of investee companies in the statement of income.

C. Navitrio

Navitrio Ltd. ("Navitrio"), a subsidiary, was founded in 2011 in order to invest in companies in the digital field. As of the reporting date, Elron directly held 85% of Navitrio's outstanding shares, and was the sole financier of Navitrio's operations.

From the date of inception of Navitrio until the reporting date, Elron invested in Navitrio an amount of \$5,000.

RDC Rafael Development Corporation Ltd ("RDC") is a holding company consolidated by Elron. Elron holds 50.1% of RDC's outstanding shares, through DEP Holding Technology Ltd, a subsidiary fully owned by Elron.

In July 2013, subsequent to the reporting date, Elron transferred its investment in Navitrio, including any rights and obligations in connection with this investment, to RDC in consideration for \$5,000, subject to adjustments. As a result, Navitrio became an RDC subsidiary. Subsequent to this transaction, RDC held 85% of Navitrio's outstanding shares.

In addition, in July 2013, subsequent to the reporting date, Navitrio signed an investment agreement with RDC, in the amount of \$2,000 in consideration for Preferred A shares. An amount of \$1,000 was advanced immediately. Subsequent to the transfer of the entire amount, RDC is expected to hold approximately 89% of Navitrio's outstanding shares.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 3 – Material Changes During the Reporting Period (Cont.)**D. Notal**

Notal Vision Inc. ("Notal") provides a system and services for remote monitoring from home of AMD patients at risk of vision loss, for the early detection of important visual changes. As of the reporting date, Elron holds approximately 23% of Notal's outstanding shares and approximately 19% on a fully diluted basis. The investment in Notal is accounted for as a financial asset measured at fair value through profit or loss.

In October 2010, Notal signed an investment agreement with its major shareholders, including Elron, and new investors, whereby approximately \$8,000 was advanced in consideration for Preferred C shares and warrants for Preferred C shares. For details regarding the investment agreement and the extension of that agreement in June 2012, see Note 3.C.1.c) to the annual consolidated financial statements.

In July 2013, subsequent to the reporting date, Notal signed an investment agreement with its major shareholders, including Elron, in the amount of \$10,000 to be advanced in two installments (Elron's share in this amount is approximately \$1,940) and an option to participate in an additional installment in the amount of \$5,000, in consideration for Preferred C shares and warrants for Preferred C shares. This agreement is an additional extension of the investment agreement signed in October 2010. The first installment in the amount of \$5,000 was advanced in July 2013. Elron's share in the first installment was approximately \$970. Elron's holding in Notal is not expected to significantly change as a result from the extension of the investment agreement.

E. Enablence

As mentioned in Note 16.H(2) to the annual consolidated financial statements, Elron holds shares and debentures of Enablence Technologies Inc. ("Enablence"). The debentures' par value is approximately \$3,779 and the investment in these debentures is treated in the financial statements as a financial asset measured at amortized cost. In 2011, due to substantial doubt in Enablence's ability to repay its debt, Elron recognized an impairment of the entire debentures balance. In 2012, Enablence paid a negligible portion of its debt to the holders of the debentures (Elron's share was approximately \$283). As a result, the Company recognized a partial cancellation of the impairment charge recognized in 2011.

In July 2013, subsequent to the reporting date, Enablence published that it might complete a financing round with a new investor in the amount of \$12,000-\$15,000 thousand CAD. If this investment will be completed, Enablence might repay a portion of its debt to the holders of the debentures, including Elron, in cash and/or in shares of Enablence.

If the aforementioned repayment will take place, Elron is expected to recognize a gain from the partial cancellation of the impairment charge recognized in 2011.

There is no assurance as to the execution of a definitive investment agreement, its terms, the completion of the agreement and/or repayment of the debt, and the timing thereof.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 3 – Material Changes During the Reporting Period (Cont.)**F. Credit Line**

As mentioned in Note 11 (1) to the annual consolidated financial statements, in 2011, Elron entered into a binding agreement with Silicon Valley Bank (the "Bank") to receive a credit line in the amount of \$30,000, which was available until May 2013 (the "Original Credit Line"). In 2012, the Company drew from the Original Credit Line, a loan in the amount of \$5,000 and later prepaid an amount of \$1,000 out of the loan balance. As of June 30, 2013 the debt balance, in accordance with the Original Credit Line, is \$4,000, to be paid in April 2015.

In order to diversify and ensure additional sources of financing for the Company towards continued investing in group companies and new companies and finance its ongoing operations, and since the Original Credit Line was not fully utilized and was about to expire, in April 2013, Elron entered into an agreement with the Bank to extend the credit line in the amount of \$25,000 (the "Credit Line Extension Agreement"). Of this amount, \$10,000 will be available until December 31, 2013 and \$15,000 will be available until October 30, 2014. During this period, the Company will be entitled to draw down loans for periods of up to 2 years from the date of each respective draw down, at the Wall Street Journal prime rate of interest plus 1.75% per annum. According to the terms of the Credit Line Extension Agreement, the Company will be able to make early repayment of all the loans at any time without any cost.

In addition, according to the Credit Line Extension Agreement, if Elron receives aggregate proceeds greater than \$30,000 from the sale of a group company ("Exit Transaction"), the Bank will have the right to demand repayment in an amount equal to 50% of the proceeds received in cash (not exceeding the amount of the outstanding debt). If Elron distributes a dividend, the Bank will have the right to demand repayment in an amount equal to the dividend distributed (not exceeding the amount of the outstanding debt). Notwithstanding, should prepayment be made following an Exit Transaction or at Elron's initiative, the Bank will not have the right to additional prepayment in the event Elron distributes a dividend up to the amount that was prepaid.

As in the Original Credit Line, the Credit Line Extension Agreement stipulates that at the time the credit line is actually utilized, the Company will pledge shares of Given Imaging Ltd. ("Given") directly held by it in an amount equal to maintain a 3.25 ratio of the market value of the pledged shares (based on their trailing 5-day average closing price prior to the computation date) to the amount of credit utilized.

As of the reporting date and as of August 12, 2013, the Company has pledged 1,130,000 Given shares held by it in favor of the Bank. The coverage ratio as of these dates is approximately 3.9 and 4.6, respectively.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 4 – Contingent Liabilities

For details regarding pending contingent liabilities and claims against the Company and its group companies as of the date of approval of the interim consolidated financial statements, see Note 15 to the annual consolidated financial statements, approved for publication on March 10, 2013.

Note 5 – Inclusion of the financial statements of associate companies accounted for under the equity method of accounting

The Company is enclosing the financial statements of Pocared in these financial statements.

The Company did not include condensed data or the financial statements of Given, a material associate company, as it reports in accordance with the reporting obligations under chapter E3 to the Israel Securities Law (1968).

Note 6 – Summarized data of the financial statements of certain associate companies, unadjusted to the Group's rate of holdings in conformity with the Israeli Securities regulations (Periodic and Immediate Reports), 1970

	<u>Current assets</u>	<u>Non-current assets</u>	<u>Total assets</u>	<u>Current liabilities</u>	<u>Non-current liabilities</u>	<u>Total liabilities</u>	<u>Equity attributable to shareholders of the company</u>	<u>Equity attributable to non-controlling interests</u>
As of June 30, 2013 (unaudited)								
BrainsGate Ltd.	12,395	171	12,566	2,272	1,197	3,469	9,097	-
Cartiheal (2009) Ltd. (*)	2,618	241	2,859	161	1,982	2,143	716	-
As of June 30, 2012 (unaudited)								
BrainsGate Ltd.	12,549	207	12,756	2,166	2,117	4,283	8,473	-
As of December 31, 2012 (audited)								
BrainsGate Ltd.	15,503	164	15,667	2,337	1,262	3,599	12,068	-
Cartiheal (2009) Ltd. (*)	4,136	138	4,274	221	2,148	2,369	1,905	-

(*) The first investment in Cartiheal (2009) Ltd. took place in July 2012, see Note 3.C.1.e) to the annual consolidated financial statements.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 6 – Summarized data of the financial statements of certain associate companies, unadjusted to the Group's rate of holdings in conformity with the Israeli Securities regulations (Periodic and Immediate Reports), 1970 (Cont.)

	Revenues	Gross profit	Operating loss	Loss from continuing operations	Loss for the period	Loss attributable to shareholders of the company	Loss attributable to non-controlling interests
For the six months period ended June 30, 2013 (unaudited)							
BrainsGate Ltd.	-	-	(3,138)	(3,015)	(3,015)	(3,015)	-
Cartiheal (2009) Ltd. (*)	-	-	(1,432)	(1,259)	(1,259)	(1,259)	-
For the six months period ended June 30, 2012 (unaudited)							
BrainsGate Ltd.	-	-	(3,205)	(3,384)	(3,384)	(3,384)	-
For the three months period ended June 30, 2013 (unaudited)							
BrainsGate Ltd.	-	-	(1,201)	(1,075)	(1,075)	(1,075)	-
Cartiheal (2009) Ltd. (*)	-	-	(664)	(574)	(574)	(574)	-
For the three months period ended June 30, 2012 (unaudited)							
BrainsGate Ltd.	-	-	(1,459)	(1,889)	(1,889)	(1,889)	-
For the year ended December 31, 2012 (audited)							
BrainsGate Ltd.	-	-	(6,207)	(6,067)	(6,067)	(6,067)	-
Cartiheal (2009) Ltd. (*)	-	-	(1,827)	(1,698)	(1,698)	(1,698)	-

(*) The first investment in Cartiheal (2009) Ltd. took place in July 2012, see Note 3.C.1.e) to the annual consolidated financial statements.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 7 – Financial instruments

A. Fair value

The carrying amount of all of the Company's financial assets and liabilities, including cash and cash equivalents, other accounts receivable, other investments measured at fair value, other long term receivables, other accounts payable, trade payables, royalty bearing government grants and long term loans from banks and others, conform to or approximate their fair values.

B. Classification of financial instruments by fair value hierarchy

The financial instruments presented in the statement of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 - inputs other than quoted prices included within Level 1 that are observable either directly or indirectly.
- Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).

Financial assets measured at fair value as of June 30, 2013:

	Level 1	Level 2	Level 3
Other investments measured at fair value	272	-	23,351

Changes in financial assets classified in Level 3:

	Financial assets measured at fair value
Balance as of January 1, 2013	23,397
Total recognized gain (loss):	
In profit or loss (*)	477
In other comprehensive income (loss)	(523)
Balance as of June 30, 2013	<u>23,351</u>
Balance as of April 1, 2013	22,874
Total recognized gain:	
In profit or loss (*)	477
Balance as of June 30, 2013	<u>23,351</u>

(*) The total gain for the period that is included in profit or loss is relating to assets held at the end of the reporting period.

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 8 – Components of comprehensive income (loss)

Six months period ended June 30, 2013 (unaudited)

	Attributable to the Company's shareholders				
	Accumulated deficit	Reserve for financial assets measured at fair value through other comprehensive income	Total	Non-controlling interests	Total
Loss	(7,633)	-	(7,633)	(650)	(8,283)
Loss from financial assets measured at fair value through other comprehensive income	-	(429)	(429)	-	(429)
Total other comprehensive loss	-	(429)	(429)	-	(429)
Total comprehensive loss	(7,633)	(429)	(8,062)	(650)	(8,712)

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 8 - Components of comprehensive income (loss) (Cont.)

Six months period ended June 30, 2012 (unaudited)

	Attributable to the Company's shareholders			Total	Non-controlling interests	Total
	Accumulated deficit	Reserve for financial assets measured at fair value through other comprehensive income	Adjustments arising from translating financial statements of foreign operations			
Net income (loss)	(3,098)	-	-	(3,098)	5,407	2,309
Loss from financial assets measured at fair value through other comprehensive income	-	(1,333)	-	(1,333)	-	(1,333)
Foreign currency translation differences for foreign operations	-	-	(50)	(50)	(3)	(53)
Total other comprehensive loss	-	(1,333)	(50)	(1,383)	(3)	(1,386)
Total comprehensive income (loss)	(3,098)	(1,333)	(50)	(4,481)	5,404	923

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 8 – Components of comprehensive income (loss) (Cont.)

Three months period ended June 30, 2013 (unaudited)

	Attributable to the Company's shareholders				
	Accumulated deficit	Reserve for financial assets measured at fair value through other comprehensive income	Total	Non-controlling interests	Total
Loss	(2,171)	-	(2,171)	(130)	(2,301)
Loss from financial assets measured at fair value through other comprehensive income	-	(107)	(107)	-	(107)
Total other comprehensive loss	-	(107)	(107)	-	(107)
Total comprehensive loss	(2,171)	(107)	(2,278)	(130)	(2,408)

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 8 – Components of comprehensive income (loss) (Cont.)

Three months period ended June 30, 2012 (unaudited)

	Attributable to the Company's shareholders			Total	Non-controlling interests	Total
	Accumulated deficit	Reserve for financial assets measured at fair value through other comprehensive income	Adjustments arising from translating financial statements of foreign operations			
Net income	3,120	-	-	3,120	6,305	9,425
Loss from financial assets measured at fair value through other comprehensive income	-	(1,086)	-	(1,086)	-	(1,086)
Foreign currency translation differences for foreign operations	-	-	(129)	(129)	(10)	(139)
Total other comprehensive loss	-	(1,086)	(129)	(1,215)	(10)	(1,225)
Total comprehensive income (loss)	3,120	(1,086)	(129)	1,905	6,295	8,200

Notes to the Interim Consolidated Financial Statements

(USD in thousands, except for price per share and number of shares)

Note 8 - Components of comprehensive income (loss) (Cont.)

Year ended December 31, 2012 (audited)

	Attributable to the Company's shareholders					
	Accumulated deficit	Reserve for financial assets measured at fair value through other comprehensive income	Adjustments arising from translating financial statements of foreign operations	Total	Non-controlling interests	Total
Net gain	4,357	-	-	4,357	11,481	15,838
Loss from financial assets measured at fair value through other comprehensive income	-	(1,313)	-	(1,313)	-	(1,313)
Adjustments arising from translating financial statements of foreign operations	-	-	(51)	(51)	(3)	(54)
Foreign currency translation differences charged to the statement of income upon disposal of foreign operations	-	-	80	80	-	80
Group's share of net other comprehensive income of companies accounted for under the equity method	141	-	-	141	23	164
Total other comprehensive income (loss)	141	(1,313)	29	(1,143)	20	(1,123)
Total comprehensive income (loss)	4,498	(1,313)	29	3,214	11,501	14,715

ANNEX TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Details regarding investments in the interim consolidated financial statements as of June 30, 2013

	<u>Rate of holdings in equity</u>		<u>Consolidated rate of holdings in equity</u>	<u>Elron's effective rate of holdings in equity (2)</u>	<u>Fully diluted consolidated rate of holdings</u>	<u>Elron's fully diluted effective rate of holdings (2)</u>	<u>Consolidated carrying value of investment June 30, 2013</u>	<u>Market value of investment</u>	
	<u>Elron (1)</u>	<u>RDC</u>						<u>June 30, 2013</u>	<u>August 12, 2013</u>
				%				\$ thousands	
Investments in investee companies									
Subsidiaries:									
Cloudyn Software Ltd.	45.94	-	45.94	39.05	43.33	36.83	63	-	-
Kyma Medical Technologies Ltd.	-	72.85	72.85	36.50	60.80	30.46	673	-	-
SmartWave Medical Ltd.	-	100	100	50.10	89.65	44.91	(74)	-	-
Associates:									
Given Imaging Ltd.	21.55	8.43	29.98	25.78	26.00	22.35	106,890	132,602	154,561
NuLens Ltd.	34.72	-	34.72	34.72	29.84	29.84	-	-	-
BrainsGate Ltd.	29.87	-	29.87	29.87	26.82	26.82	1,871	-	-
Pocared Diagnostics Ltd.	41.35	-	41.35	41.35	37.67	37.67	3,006	-	-
Cartiheal (2009) Ltd.	23.86	-	23.86	23.86	27.55	27.55	1,144	-	-
Numbeez Ltd.	34.48	-	34.48	29.31	34.29	29.15	105	-	-
Pose POS Ltd. (formerly Blits Branding Ltd.)	31.42	-	31.42	26.71	26.09	22.18	94	-	-
Plymedia Inc.	27.68	-	27.68	27.68	19.70	19.70	-	-	-
Other investments:									
Notal Vision Inc.	23.10	-	23.10	23.10	18.85	18.85	6,937	-	-
Jordan Valley Semiconductors Ltd.	18.83	-	18.83	18.83	16.95	16.95	11,380	-	-
Atlantium Technologies Inc.	8.05	-	8.05	8.05	6.91	6.91	130	-	-
Aqwise – Wise Water Technologies Ltd.	19.81	-	19.81	19.81	17.94	17.94	4,290	-	-
Enablence Technologies Inc.	2.88	-	2.88	2.88	N/A	N/A	272	272	389
Whitewater Ltd.	2.90	-	2.90	2.90	1.45	1.45	549	-	-

(1) Including holding through Elron's fully-owned subsidiaries and through Navitrio.

(2) Elron's effective holdings include holdings by RDC multiplied by 50.10% and holdings by Navitrio multiplied by 85%.

(3) The rates of holding are as of June 30, 2013. Regarding the transfer of the investment in Navitrio from Elron to RDC in July 2013, see Note 3.C above.

POCARED DIAGNOSTICS LTD.
(A development stage company)

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2013

U.S. DOLLARS IN THOUSANDS

UNAUDITED

INDEX

	<u>Page</u>
Review of Unaudited Interim Financial Statements	P-2
Consolidated Balance Sheets	P-3 – P-4
Consolidated Statements of Operations	P-5
Statements of Changes in Shareholders' Equity (Deficiency)	P-6 – P-8
Consolidated Statements of Cash Flows	P-9
Notes to Consolidated Financial Statements	P-10 - P-15



Kost Forer Gabbay & Kasierer
3 Aminadav St.
Tel-Aviv 67067, Israel

Tel: 972 (3)6232525
Fax: 972 (3)5622555
www.ey.com

The Board of Directors
Pocared Diagnostics Ltd. (a development stage company)

Re: Auditors report on review to the Shareholders of Pocared
Diagnostics LTD (a development stage company)

We have reviewed the accompanying financial information of Pocared Diagnostics Ltd. and its subsidiary (a development stage company) (together "the Company") which comprises the condensed balance sheet as of June 30, 2013 and 2012 and the related condensed consolidated statements of operations, changes in shareholders' equity (deficiency) and cash flows for the six and three months period ended June 30, 2013 and 2012 and for the period from January 1, 2005 (date of inception) through June 30, 2013. This condensed financial information is the responsibility of the Company's management.

We conducted our review in accordance with Review Standard 1 of the Institute of Certified Public Accountants in Israel, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards in Israel and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial information referred to above in order for them to be in conformity with United States generally accepted accounting principles, which differ in certain aspects from international financial reporting standards, as described in note 5 to the consolidated financial statements.

The accompanying financial information has been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the condensed consolidated financial statements, the Company has incurred losses in the amount of \$ 4,137 thousand during the six month period ended June 30, 2013, has an accumulated deficit during the development stage of \$ 59,590 thousand as of June 30, 2013, and has an accumulated negative cash flow from operating activities. These factors raise substantial doubt about the Company's ability to continue as a going concern (Management's plans in regard to these matters are described in Note 1c). The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company unable to continue as a going concern.

Tel-Aviv, Israel
July 29 , 2013

KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	June 30,		December 31,
	2013	2012	2012
	Unaudited		
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	\$ 4,100	\$ 4,897	\$ 2,047
Short-term bank deposit	433	550	-
Restricted cash	144	90	99
Inventory	855	846	802
Accounts receivable	171	196	222
Total current assets	5,703	6,579	3,170
PROPERTY AND EQUIPMENT, NET	857	793	710
LONG-TERM DEPOSIT	17	18	16
Total assets	\$ 6,577	\$ 7,390	\$ 3,896

The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

	June 30,		December 31,
	2013	2012	2012
	Unaudited		
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)			
CURRENT LIABILITIES:			
Trade payables	\$ 276	\$ 96	\$ 168
Employees and payroll accruals	270	209	304
Accrued expenses	382	195	418
Total current liabilities	928	500	890
CONVERTIBLE PREFERRED SHARES (Note 4)			
Preferred A shares, NIS 0.01 par value; Authorized: 1,500,000 shares at June 30, 2013 and 2012 and December 31, 2012; Issued and outstanding: 1,333,333 shares at June 30, 2013 and 2012 and December 31, 2012	300	300	300
Preferred B shares, NIS 0.01 par value; Authorized: 1,550,000 shares at June 30, 2013 and 2012 and December 31, 2012; Issued and outstanding: 1,507,341 shares at June 30, 2013 and 2012 and December 31, 2012	1,634	1,634	1,634
Preferred C shares, NIS 0.01 par value; Authorized: 1,000,000 shares at June 30, 2013 and 2012 and December 31, 2012; Issued and outstanding: 760,501 shares at June 30, 2013 and 2012 and December 31, 2012	1,280	1,280	1,280
Preferred D, D-1, and D-2 shares, NIS 0.01 par value; Authorized: 9,660,000 shares at June 30, 2013 and 2012 and December 31, 2012; Issued and outstanding: 9,573,601 shares at June 30, 2013 and 2012 and December 31, 2012	25,288	25,288	25,288
Preferred E shares, NIS 0.01 par value; Authorized: 11,000,000 shares at March 31, 2013 and 2012 and December 31, 2012; Issued and outstanding: 10,413,052 shares at June 30, 2013 and 2012 and December 31, 2012	6,548	6,548	6,548
Preferred F shares, NIS 0.01 par value; Authorized: 66,000,000 shares at June 30, 2013 and 44,000,000 shares at June 30, 2012 and December 31, 2012; Issued and outstanding: 48,302,205 and 37,172,832 and 37,172,832 shares at June 30, 2013 and 2012 and December 31, 2012, respectively.	29,195	22,462	22,462
Liquidation preference of Preferred shares at June 30, 2013 amounted to \$ 107,220			
	64,245	57,512	57,512
SHAREHOLDERS' DEFICIENCY:			
Ordinary shares, NIS 0.001 par value; Authorized: 113,000,000 share as of June 30, 2013 and 2012 (unaudited) and December 31, 2012; Issued and outstanding: 2,000,000 shares as of June 30, 2013 and 2012 (unaudited) and December 31, 2012;	4	4	4
Additional paid-in capital	990	893	943
Deficit accumulated during the development stage	(59,590)	(51,519)	(55,453)
Total shareholders' deficiency	(58,596)	(50,622)	(54,506)
Total liabilities and shareholders' deficiency	\$ 6,577	\$ 7,390	\$ 3,896

The accompanying notes are an integral part of the interim consolidated financial statements.

July 29, 2013			
Date of approval of the financial statements	Avi Ludomirski Chairman of the Board	Jonathan Gurfinkel Chief Executive Officer	Michal Mendelevich levy Finance Manager

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands

	Six months ended June 30,		Three months ended June 30,		Year ended December 31, 2012	Period from January 1, 2005 (inception date) through June 30, 2013
	2013	2012	2013	2012		
	Unaudited					Unaudited
Operating expenses:						
Research and development	\$ 2,887	\$ 2,009	\$ 1,684	\$ 1,253	\$ 4,964	\$ 48,842
Marketing	96	143	41	89	253	593
General and administrative	1,147	979	613	440	1,852	9,475
Operating loss	4,130	3,131	2,338	1,782	7,069	58,910
Financial expenses (income), net	(13)	(16)	-	35	(26)	551
Loss before income taxes	4,117	3,115	2,338	1,817	7,043	59,461
Income taxes	20	27	9	15	33	129
Net loss	\$ 4,137	\$ 3,142	\$ 2,347	\$ 1,832	\$ 7,076	\$ 59,590

The accompanying notes are an integral part of the interim consolidated financial statements.

STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' EQUITY (DEFICIENCY)

U.S. dollars in thousands, except share data

	Convertible Preferred shares		Ordinary shares		Additional paid-in capital	Deficit accumulated during the development stage	Total shareholders' equity (deficiency)
	Number	Amount	Number	Amount			
Balance as of January 1, 2005 (inception date)	-	\$ -	-	\$ -	\$ -	\$ -	\$ -
Issuance of Ordinary shares, net in January 1, 2005	-	-	2,000,000	4	-	-	4
Issuance of Preferred A shares (at \$0.22), net	1,333,333	300	-	-	-	-	-
Stock-based compensation related to options granted to service providers	-	-	-	-	6	-	6
Net loss	-	-	-	-	-	(669)	(669)
Balance as of December 31, 2005 (unaudited)	1,333,333	300	2,000,000	4	6	(669)	(659)
Issuance of Preferred B shares (at \$1.08), net	1,507,341	1,634	-	-	-	-	-
Issuance of preferred C shares (at \$1.68)	760,501	1,280	-	-	-	-	-
Stock based compensation related to options granted to service providers	-	-	-	-	45	-	45
Net loss	-	-	-	-	-	(1,918)	(1,918)
Balance as of December 31, 2006	3,601,175	3,214	2,000,000	4	51	(2,587)	(2,532)
Issuance of Preferred D shares (at \$2.29)	2,982,896	6,832	-	-	-	-	-
Stock based compensation related to options granted to service providers and employees	-	-	-	-	107	-	107
Net loss	-	-	-	-	-	(7,558)	(7,558)
Balance as of December 31, 2007	6,584,071	10,046	2,000,000	4	158	(10,145)	(9,983)
Issuance of Preferred D shares (at \$2.32)	1,606,176	3,735	-	-	-	-	-
Stock based compensation related to options granted to service providers and employees	-	-	-	-	118	-	118
Net loss	-	-	-	-	-	(18,070)	(18,070)
Balance as of December 31, 2008	8,190,247	\$ 13,781	2,000,000	\$ 4	\$ 276	\$ (28,215)	\$ (27,935)

The accompanying notes are an integral part of the interim consolidated financial statements.

STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY

U.S. dollars in thousands, except share data

	Convertible Preferred shares		Ordinary shares		Additional paid-in capital	Deficit accumulated during the development stage	Total shareholders' equity (deficiency)
	Number	Amount	Number	Amount			
Balance as of December 31, 2008	8,190,247	\$ 13,781	2,000,000	\$ 4	\$ 276	\$ (28,215)	\$ (27,935)
Conversion of convertible loan to Preferred D-1 shares	4,924,722	14,700	-	-	-	-	-
Exercise of option granted to service provider	59,807	21	-	-	-	-	-
Issuance of Preferred E shares (at \$0.63)	10,413,052	6,548	-	-	-	-	-
Stock based compensation related to options granted to service providers and employees	-	-	-	-	143	-	143
Net loss	-	-	-	-	-	(10,653)	(10,653)
Balance as of December 31, 2009	23,587,828	35,050	2,000,000	4	419	(38,868)	(38,445)
Stock based compensation related to options granted to service providers and employees	-	-	-	-	174	-	174
Net loss	-	-	-	-	-	(3,953)	(3,953)
Balance as of December 31, 2010	23,587,828	35,050	2,000,000	4	593	(42,821)	(42,224)
Issuance of Preferred F shares (at \$0.605)	21,928,376	13,250	-	-	-	-	-
Conversion of convertible loan into Preferred F shares (at \$0.605)	15,244,456	9,212	-	-	-	-	-
Stock based compensation related to options granted to service providers and employees	-	-	-	-	224	-	224
Net loss	-	-	-	-	-	(5,556)	(5,556)
Balance as of December 31, 2011	60,760,660	57,512	2,000,000	4	817	(48,377)	(47,556)
Stock based compensation related to options granted to service providers and employees	-	-	-	-	126	-	126
Net loss	-	-	-	-	-	(7,076)	(7,076)
Balance as of December 31, 2012	60,760,660	57,512	2,000,000	4	943	(55,453)	(54,506)
Issuance of Preferred F shares (at \$0.605)	11,129,374	6,733	-	-	-	-	-
Stock based compensation related to options granted to service providers and employees	-	-	-	-	47	-	47
Net loss	-	-	-	-	-	(4,137)	(4,137)
Balance as of June 30, 2013 (unaudited)	71,890,034	\$ 64,245	2,000,000	\$ 4	\$ 990	\$ (59,590)	\$ (58,596)

The accompanying notes are an integral part of the interim consolidated financial statements.

STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY

U.S. dollars in thousands, except share data

	Convertible Preferred shares		Ordinary shares		Additional paid-in capital	Deficit accumulated during the development stage	Total shareholders' equity (deficiency)
	Number	Amount	Number	Amount			
Balance as of January 1, 2012	60,760,660	\$ 57,512	2,000,000	\$ 4	\$ 817	\$ (48,377)	\$ (47,556)
Stock based compensation related to options granted to service providers and employees	-	-	-	-	76	-	76
Net loss	-	-	-	-	-	(3,142)	(3,142)
Balance as of June 30, 2012 (unaudited)	60,760,660	\$ 57,512	2,000,000	\$ 4	\$ 893	\$ (51,519)	\$ (50,622)

The accompanying notes are an integral part of the interim consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Six months ended June 30,		Three months ended June 30,		Year ended	Period from
	2013	2012	2013	2012	December 31,	January 1, 2005
	Unaudited					
					2012	2013
						Unaudited
Cash flows from operating activities:						
Net loss	\$ (4,137)	\$ (3,142)	\$ (2,347)	\$ (1,832)	\$ (7,076)	\$ (59,590)
Adjustments required to reconcile net loss to net cash used in operating activities:						
Depreciation	109	107	57	55	213	581
Increase in interest on convertible loan	-	-	-	-	-	941
Revaluation of restricted cash	12	1	(3)	4	(3)	15
Stock-based compensation related to employees and service providers	47	76	26	36	126	990
Decrease (increase) in inventory	(53)	407	48	500	451	(855)
Decrease (increase) in accounts receivable	51	(12)	90	(11)	2	(171)
Increase in long-term deposit	(1)	-	(2)	-	-	(16)
Increase (decrease) in trade payables	108	(112)	108	(33)	(40)	276
Increase (decrease) in accrued expenses	(36)	(88)	(80)	37	135	382
Increase (decrease) in employees and payroll accruals	(34)	(25)	(21)	2	70	270
Net cash used in operating activities	(3,934)	(2,788)	(2,124)	(1,242)	(6,160)	(57,177)
Cash flows from investing activities:						
Investment in restricted cash	(57)	(15)	-	(15)	(20)	(159)
Proceeds from short-term deposit	-	2,011	-	270	2,011	2,011
Investment in short-term deposit	(433)	(550)	(433)	(550)	-	(2,011)
Purchase of property and equipment	(256)	(98)	(154)	(12)	(121)	(1,438)
Net cash provided by (used in) investing activities	(746)	1,348	(587)	(307)	1,870	(1,597)
Cash flows from financing activities:						
Proceeds from convertible loan	-	-	-	-	-	22,982
Proceeds from issuance of Preferred shares, net	6,733	-	3,000	-	-	40,325
Net cash provided by financing activities	6,733	-	3,000	-	-	63,307
Increase (decrease) in cash and cash equivalents	2,053	(1,440)	289	(1,549)	(4,290)	4,533
Cash and cash equivalents at beginning of period	2,047	6,337	3,811	6,446	6,337	-
Cash and cash equivalents at end of period	\$ 4,100	\$ 4,897	\$ 4,100	\$ 4,897	\$ 2,047	\$ 4,533

The accompanying notes are an integral part of the interim consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 1:- GENERAL

- a. Pocared Diagnostics Ltd. ("the Company") was founded in 2004 and began its operation in January 2005. The Company has developed an innovative technological platform for fully automated, real-time diagnosis of contaminants suspended in liquids. The Company develops a real-time, fully automated laboratory based system for the in-vitro diagnostics (IVD) industry, and specifically for the microbiology market.

The Company's technology and System address the demands for greater throughput and test accuracy. The Company's testing platform can analyze different types of specimens, including urine, swabs, sputum, blood, CSF and feces. The first application to be released is for diagnosis of Urinary Tract Infection. The Company's system is at development stage and it is not available for use at the US.

- b. On January 1, 2008, the Company's wholly-owned subsidiary, Pocared Diagnostics, Inc. ("the Subsidiary"), commenced operations in the USA. Accordingly, Pocared Diagnostics, Inc. is consolidated from the date mentioned above in the Company's financial statements.

The Company and the Subsidiary are parties to a service agreement under which all research and development expenditures incurred by the Subsidiary are reimbursed by the Company on a cost-plus basis.

- c. Since its inception, the Company has devoted substantially most of its efforts to business planning, research and development. In addition, the Company has not generated revenues. Accordingly, the Company is considered to be in the development stage, as defined in ASC 915 "Development Stage Entities".

The Company has incurred losses in the amount of \$ 4,137 during the six months ended June 30, 2013, , has an accumulated deficit during the development stage of \$ 59,590 as of June 30, 2013 and has accumulated negative cash flow from operating activities.

The Company plans to continue to finance its operations, as it has in the past, through the private placements. The Company cannot, however, give any assurance that it will in the future continue to be successful in obtaining such additional necessary financing.

These factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in the financial statements as of June 30, 2013, are consistent with those applied in the financial statements as of December 31, 2012.

These financial statements should be read in conjunction with the audited annual consolidated financial statements of the Company as of December 31, 2012 and their accompanying notes.

NOTE 3:- UNAUDITED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited interim financial statements have been prepared in accordance with accounting United States generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six three months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

NOTE 4:- CONVERTIBLE PREFERRED SHARES

Share issuance:

1. On January 10, 2011, the Company effected a private placement and issued 9,586,777 Preferred F shares in consideration of \$ 5,800. According to the share purchase agreement, the Company will issue up to an additional 18,512,397 Preferred F shares in consideration of up to \$ 11,200 in three equal quarterly installments starting April 1, 2011. On March 21, 2011, the Company's board of directors resolved to postpone the quarterly installments by 8 weeks. On March 31, 2011, the Company's shareholders approved the above mentioned postponement.
2. On January 10, 2011, the convertible loan and accrued interest were converted into 15,244,456 Preferred F shares.
3. On May 27, 2011 the Company received the second installment (Note 4(1) above) and issued 6,170,799 shares in consideration of \$ 3,733.
4. On September 8, 2011 the Company received the third installment (Note 4(1) above) and issued 6,170,799 shares in consideration of \$ 3,733.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 4:- CONVERTIBLE PREFERRED SHARES (Cont.)

5. On December 5, 2011, the Company's shareholders resolved to postpone the fourth installment to March 30, 2012. On March 22, 2012 the Company's board of directors resolved to postpone the fourth installment to November, 2012. notwithstanding the aforesaid if the performance issue is resolved at any time before such date the Company shall be authorized to immediately call the money and investors shall committed to make such investment. This board of director resolution is still subject to shareholders' approval.
6. On February 18, 2013 the Company received the fourth installment (Note 4(1) above) and issued 6,170,799 shares in consideration of \$ 3,733.
7. In May 13,2013 the Company effected a private placement. On June 9,2013 the Company issued and 4,958,678 Preferred F shares in consideration of the first installment of \$ 3,000. Under this private placement the Company will issue up to an additional 11,570,925 Preferred F shares in consideration of up to \$ 7,000 based on completion stipulated milestone.

NOTE 5:- RECONCILIATION TO "INTERNATIONAL FINANCIAL REPORTING STANDARDS"

- a. According to International Financial Reporting Standards ("IFRS"), a convertible loan and its convertible element should be presented at its fair market value, based on its classification as a financial liability at Fair Value through profit and loss. According to U.S. GAAP, a convertible loan is presented at its nominal value. The Company's Convertible note had been accounted accordingly.

As of January 10, 2011, the Company no longer had any convertible notes outstanding; therefore, no further adjustment between IFRS and U.S. GAAP due to the convertible loan were deemed necessary.

- b. According to International Financial Reporting Standards ("IFRS"), the redemption convertible preferred shares should be presented as equity since the event may trigger the redemption are in the control of the entity as the board approval is required and the board represents the Company according to IFRS. According to U.S. GAAP in accordance with ASC 480 the redeemable convertible preferred shares are presented outside of permanent equity.
- c. Reconciliations to the statement of income, as of June 30,2013 since the redemption event is not probable no adjustment to the value under U.S. GAAP has been recorded and therefore no income statement difference between U.S. GAAP and IFRS exists.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6: - STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) ACCORDING TO IFRS (Cont.)

	Shareholders' deficiency attributable to equity holders of the parent														Deficit accumulated during the development stage	Total shareholders' equity (deficiency)		
	Ordinary shares		Preferred A shares		Preferred B shares		Preferred C shares		Preferred D, D-1 and D-2 shares		Preferred E shares		Preferred F shares				Additional paid-in capital	
	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount				
Balance at January 1, 2005 (inception date)	-	\$ -	-	\$ -	-	\$ -	-	\$ -	-	\$ -	-	\$ -	-	\$ -	-	\$ -	-	\$ -
Issuance of Ordinary shares, net in January 1, 2005	2,000,000	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4
Issuance of Preferred A shares (at \$0.22), net	-	-	1,333,333	3	-	-	-	-	-	-	-	-	-	-	297	-	-	300
Stock-based compensation related to options granted to service providers	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-	-	6
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(669)	(669)
Balance at December 31, 2005 (unaudited)	2,000,000	4	1,333,333	3	-	-	-	-	-	-	-	-	-	303	-	-	(669)	(359)
Issuance of Preferred B shares (at \$1.08), net	-	-	-	-	1,507,341	3	-	-	-	-	-	-	-	1,631	-	-	-	1,634
Issuance of preferred C shares (at \$1.68)	-	-	-	-	-	-	760,501	2	-	-	-	-	-	1,278	-	-	-	1,280
Stock based compensation related to options granted to service providers	-	-	-	-	-	-	-	-	-	-	-	-	-	45	-	-	-	45
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(1,918)	(1,918)
Balance at December 31, 2006	2,000,000	4	1,333,333	3	1,507,341	3	760,501	2	-	-	-	-	-	3,257	-	-	(2,587)	682
Issuance of Preferred D shares (at \$2.29)	-	-	-	-	-	-	-	-	2,982,896	7	-	-	-	6,825	-	-	-	6,832
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	107	-	-	-	107
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(7,558)	(7,558)
Balance at December 31, 2007	2,000,000	4	1,333,333	3	1,507,341	3	760,501	2	2,982,896	7	-	-	-	10,189	-	-	(10,145)	63
Issuance of Preferred D shares (at \$2.32)	-	-	-	-	-	-	-	-	1,606,176	4	-	-	-	3,731	-	-	-	3,735
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	118	-	-	-	118
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(18,070)	(18,070)
Balance at December 31, 2008	2,000,000	\$ 4	1,333,333	\$ 3	1,507,341	\$ 3	760,501	\$ 2	4,589,072	\$ 11	\$ -	\$ -	\$ -	\$ 14,038	\$ -	\$ -	\$(28,215)	\$(14,154)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6:- STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) ACCORDING TO IFRS (Cont.)

	Shareholders' deficiency attributable to equity holders of the parent															Deficit accumulated during the development stage	Total shareholders' equity (deficiency)
	Ordinary shares		Preferred A shares		Preferred B shares		Preferred C shares		Preferred D, D-1 and D-2 shares		Preferred E shares		Preferred F shares		Additional paid-in capital		
	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount			
Balance at December 31, 2008	2,000,000	\$ 4	1,333,333	\$ 3	1,507,341	\$ 3	760,501	\$ 2	4,589,072	\$ 11	\$ -	\$ -	\$ -	\$ -	\$ 14,038	\$ (28,215)	\$ (14,154)
Conversion of convertible loan to preferred D-1 shares	-	-	-	-	-	-	-	-	4,924,722	49	-	-	-	-	17,531	-	17,580
Exercise of option granted to service provider	-	-	-	-	-	-	-	-	59,807	1	-	-	-	-	20	-	21
Issuance of Preferred E shares (at \$0.63)	-	-	-	-	-	-	-	-	-	-	10,413,052	25	-	-	6,523	-	6,548
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-	143	-	143
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(13,533)	(13,533)
Balance at December 31, 2009	2,000,000	4	1,333,333	3	1,507,341	3	760,501	2	9,573,601	61	10,413,052	25	-	-	38,255	(41,748)	(3,395)
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-	174	-	174
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(3,679)	(3,679)
Balance at December 31, 2010	2,000,000	4	1,333,333	3	1,507,341	3	760,501	2	9,573,601	61	10,413,052	25	-	-	38,429	(45,427)	(6,900)
Issuance of Preferred F shares (at \$ 0.605)	-	-	-	-	-	-	-	-	-	-	-	-	37,172,832	104	22,084	-	22,188
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-	224	-	224
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(5,556)	(5,556)
Balance at December 31, 2011	2,000,000	4	1,333,333	3	1,507,341	3	760,501	2	9,573,601	61	10,413,052	25	37,172,832	104	60,737	(50,983)	9,956
Stock based compensation related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126	-	126
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(7,076)	(7,076)
Balance at December 31, 2012	2,000,000	\$ 4	1,333,333	\$ 3	1,507,341	\$ 3	760,501	\$ 2	9,573,601	\$ 61	10,413,052	\$ 25	37,172,832	\$ 104	\$ 60,863	\$ (58,059)	\$ 3,006

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6:- STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) ACCORDING TO IFRS (Cont.)

	Shareholders' deficiency attributable to equity holders of the parent															Deficit accumulated during the development stage	Total shareholders' equity (deficiency)
	Ordinary shares		Preferred A shares		Preferred B shares		Preferred C shares		Preferred D, D-1 and D-2 shares		Preferred E shares		Preferred F shares		Additional paid-in capital		
	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount	Number	Amount			
Balance at December 31, 2012	2,000,000	\$ 4	1,333,333	\$ 3	1,507,341	\$ 3	760,501	\$ 2	9,573,601	\$ 61	10,413,052	\$ 25	37,172,832	\$ 104	\$ 60,863	\$ (58,059)	\$ 3,006
Issuance of Preferred F shares (at \$ 0.605)	-	-	-	-	-	-	-	-	-	-	-	-	11,129,373	31	6,702	-	6,733
Stock based compensat related to options granted to service providers and employees	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47	-	47
Net loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(4,137)	(4,137)
Balance at June 30, 2013 (unaudited)	<u>2,000,000</u>	<u>\$ 4</u>	<u>1,333,333</u>	<u>\$ 3</u>	<u>1,507,341</u>	<u>\$ 3</u>	<u>760,501</u>	<u>\$ 2</u>	<u>9,573,601</u>	<u>\$ 61</u>	<u>10,413,052</u>	<u>\$ 25</u>	<u>48,302,205</u>	<u>\$ 135</u>	<u>\$ 67,612</u>	<u>\$ (62,196)</u>	<u>\$ 5,649</u>

Elron Electronic Industries Ltd.
English Translation of Financial Data from the
Interim Consolidated Financial Statements
Attributable to the Company

As of
June 30, 2013
Unaudited

Contents

	<u>Page</u>
Special report to the review of the separate interim financial information according to Regulation 38D	S-2
Special Report according to Regulation 38D	S-3
Data from the Interim Consolidated Financial Statements on the Financial Position Attributable to the Company	S-4-S-5
Data from the Interim Consolidated Financial Statements on the Income Attributable to the Company	S-6
Data from the Interim Consolidated Financial Statements on the Comprehensive Income Attributable to the Company	S-7
Data from the Interim Consolidated Financial Statements on the Cash Flows Attributable to the Company	S-8-S-9
Additional Information	S-10

Special report to the review of the separate interim financial information in accordance with Regulation 38d to the Israeli Securities Regulations (Periodic and Immediate Reports), 1970

Introduction

We have reviewed the interim financial information disclosed in accordance with Regulation 38d to the Israeli Securities Regulations (Periodic and Immediate Reports), 1970 of Elron Electronic Industries Ltd. ("the Company") as of June 30, 2013 and for the six and three months then ended. The Company's board of directors and management are responsible for the separate interim financial information. Our responsibility is to express a conclusion on the separate interim financial information based on our review.

We did not review the separate interim financial information taken from the financial statements of an investee, whose assets less attributable liabilities net, totaled approximately \$ 44 million as of June 30, 2013 and the earnings from the investee amounted to approximately \$ 1,066 thousand and \$ 1,099 thousand for the six and three months then ended, respectively. The financial statements of that company were reviewed by other auditors, whose review reports have been furnished to us, and our conclusion, insofar as it relates to the financial statements in respect of that company, is based on the review reports of the other auditors.

Scope of review

We conducted our review in accordance with Review Standard I of the Institute of Certified Public Accountants in Israel, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards in Israel and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review and the review reports of other auditors, nothing has come to our attention that causes us to believe that the accompanying separate interim financial information is not prepared, in all material respects, in accordance with Regulation 38d to the Securities Regulations (Periodic and Immediate Reports), 1970.

Tel-Aviv, Israel
August 13, 2013

KOST FORER GABBAY & KASIERER
A Member of Ernst & Young Global

Special Report according to Regulation 38D
Financial Data and Information from the Interim Consolidated Financial Statements
Attributable to Elron Electronic Industries Ltd. ("the Company")

The following separate financial data and information attributable to the Company ("separate data") are derived from the Company's Interim Consolidated Financial Statements as of June 30, 2013, and for the six and three months then ended ("interim consolidated financial statements"), which form part of the Company's periodic reports. The separate data are presented in accordance with Regulation 38D of the Israel Securities Regulations (Periodic and Immediate Reports) - 1970.

The significant accounting policies followed in the preparation of the following separate data are identical to those applied in the preparation of the Company's consolidated annual financial statements for the year ended December 31, 2012 ("consolidated financial statements for 2012") and the Company's interim consolidated financial statements, apart from differences arising from compliance with the aforementioned regulations.

Presentation of transactions which were eliminated in the interim consolidated financial statements

Intercompany balances, transactions and cash flows between the Company and its subsidiaries were eliminated in the preparation of the Company's interim consolidated financial statements.

In the separate data, such transactions are presented as follows:

- Financial position data attributable to the Company include balances in respect of the Company's subsidiaries which were eliminated in the interim consolidated financial statements.
- Income and loss data attributable to the Company include income and expenses of the Company resulting from transactions with its subsidiaries, which were eliminated in the interim consolidated financial statements.
- Cash flow data attributable to the Company include cash flows between the Company and its subsidiaries which were eliminated in the interim consolidated financial statements.

Data from the Interim Consolidated Financial Statements on the Financial Position Attributable to the Company as of

	June 30		December 31
	2013	2012	2012
	Unaudited		Audited
	\$ thousands		
Current assets			
Cash and cash equivalents	20,741	48,215	25,097
Other accounts receivable	490	3,024	2,757
	<u>21,231</u>	<u>51,239</u>	<u>27,854</u>
Assets held for sale	<u>-</u>	<u>651</u>	<u>-</u>
Non-current assets			
Investments in subsidiaries and associates, net	194,875	188,576	193,296
Other investments measured at fair value	23,335	17,636	23,287
Property, plant and equipment, net	44	59	45
Other long-term receivables	216	220	183
	<u>218,470</u>	<u>206,491</u>	<u>216,811</u>
Total assets	<u>239,701</u>	<u>258,381</u>	<u>244,665</u>

The accompanying additional information is an integral part of the separate financial data and information.

Data from the Interim Consolidated Financial Statements on the Financial Position Attributable to the Company as of

	June 30		December 31
	2013	2012	2012
	Unaudited		Audited
	\$ thousands		
Current liabilities			
Trade payables	67	99	95
Other accounts payable	1,554	11,168	1,633
Dividend payables	-	15,000	-
	<u>1,621</u>	<u>26,267</u>	<u>1,728</u>
Long-term liabilities			
Loans from banks	4,000	5,000	4,000
Other long term liabilities (Note 2)	79,341	73,172	76,897
	<u>83,341</u>	<u>78,172</u>	<u>80,897</u>
Equity attributable to the Company's shareholders			
Issued capital	9,573	9,573	9,573
Share premium	190,753	190,378	190,709
Capital reserves	(9,580)	(10,039)	(9,868)
Accumulated deficit	(36,007)	(35,970)	(28,374)
	<u>154,739</u>	<u>153,942</u>	<u>162,040</u>
Total equity	<u><u>239,701</u></u>	<u><u>258,381</u></u>	<u><u>244,665</u></u>

The accompanying additional information is an integral part of the separate financial data and information.

Arie Mientkavich
Chairman of the Board of Directors

Ari Bronshtein
Chief Executive Officer

Yaron Elad
Vice President &
Chief Financial Officer

Approval date of the interim consolidated financial statements: August 13, 2013

Data from the Interim Consolidated Financial Statements on the Income Attributable to the Company

	Six months ended		For the		Year ended
	June 30		Three months ended		December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
Income					
Financial income (Note 2)	154	2,686	48	4,057	892
Cost and expenses					
General and administrative expenses	2,031	1,998	1,041	997	3,873
Financial expenses (Note 2)	2,533	1,648	813	1,263	3,455
Other expenses, net	17	500	12	500	159
	4,581	4,146	1,866	2,760	7,487
	(4,427)	(1,460)	(1,818)	1,297	(6,595)
Gain from disposal of subsidiaries and associates, revaluation of investee companies and changes in holdings, net					
	1,549	1,904	1,435	2,405	10,006
Company's share of income (loss) of subsidiaries and associates	(4,755)	(3,542)	(1,788)	(582)	946
Net income (loss) attributable to the Company's shareholders	(7,633)	(3,098)	(2,171)	3,120	4,357

The accompanying additional information is an integral part of the separate financial data and information.

Data from the Interim Consolidated Financial Statements on the Comprehensive Income Attributable to the Company

	For the				
	Six months ended June 30		Three months ended June 30		Year ended December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
\$ thousands					
Net income (loss) attributable to the Company's shareholders	(7,633)	(3,098)	(2,171)	3,120	4,357
Other comprehensive income (loss):					
Amounts that would never be reclassified to profit or loss:					
Loss from financial assets measured at fair value through other comprehensive income, net	(429)	(1,333)	(107)	(1,086)	(1,313)
Total loss that would never be reclassified to profit or loss	(429)	(1,333)	(107)	(1,086)	(1,313)
Amounts that are classified or may be reclassified to profit or loss under certain conditions:					
Foreign currency translation differences for foreign operations	-	(50)	-	(125)	(51)
Foreign currency translation differences charged to the statement of income upon disposal of foreign operations	-	-	-	-	80
Total gain (loss) that would be reclassified to profit or loss	-	(50)	-	(125)	29
Total other comprehensive loss attributable to the Company	(429)	(1,383)	(107)	(1,211)	(1,284)
Other comprehensive income (loss) attributable to the Company's subsidiaries and associates	-	-	-	(4)	141
Total comprehensive income (loss) attributable to the Company's shareholders	(8,062)	(4,481)	(2,278)	1,905	3,214

The accompanying additional information is an integral part of the separate financial data and information.

Data from the Interim Consolidated Financial Statements on the Cash Flows Attributable to the Company

	Six months ended		For the		Year ended
	June 30		Three months ended		
	2013	2012	2013	2012	2012
	Unaudited				Audited
\$ thousands					
Cash flows from operating activities					
Net income (loss) attributable to the Company	(7,633)	(3,098)	(2,171)	3,120	4,357
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:					
Adjustment to the profit or loss items:					
Company's share of loss (income) of subsidiaries and associates	4,755	3,542	1,788	582	(946)
Depreciation	7	14	4	7	26
Financial expenses (income), net	39	(135)	25	(16)	(203)
Change in liabilities in respect of options	(21)	(16)	(11)	(9)	(38)
Gain from disposal of subsidiaries and associates, revaluation of investee companies and changes in holdings, net	(1,549)	(1,904)	(1,435)	(2,405)	(10,006)
Change in fair value of financial assets measured at fair value, net	-	1,317	-	1,185	1,407
Other	(259)	(9)	(52)	295	(286)
	2,972	2,809	319	(361)	(10,046)
Changes in assets and liabilities of the Company:					
Decrease (increase) in other accounts receivable	344	147	62	(2)	(235)
Increase in long term receivables	(33)	(138)	(12)	(41)	(180)
Increase (decrease) in trade payables	(28)	(3)	15	(85)	(7)
Increase (decrease) in other accounts payable	(58)	9,363	(497)	9,580	8,978
Increase (decrease) in other long term liabilities	2,444	(1,953)	652	(4,097)	1,771
	2,669	7,416	220	5,355	10,327
Cash paid and received during the period for:					
Interest paid	(80)	-	(40)	-	(84)
Interest received	41	135	15	16	287
	(39)	135	(25)	16	203
Net cash provided by (used in) operating activities	(2,031)	7,262	(1,657)	8,130	4,841

The accompanying additional information is an integral part of the separate financial data and information.

Data from the Interim Consolidated Financial Statements on the Cash Flows Attributable to the Company (Cont.)

	Six months ended		For the		Year ended
	June 30		Three months ended		December 31
	2013	2012	2013	2012	2012
	Unaudited				Audited
	\$ thousands				
Cash flows from investment activities					
Purchase of property and equipment	(6)	(3)	(6)	-	(6)
Investment in associates and subsidiaries	(4,308)	(5,341)	(1,646)	(1,500)	(13,630)
Proceeds from sale of property and equipment	-	-	-	-	5
Proceeds from sale of investments in associates and subsidiaries	1,945	5,405	-	5,383	7,341
Proceeds from sale of financial assets measured at fair value	-	1,708	-	1,086	1,748
Repayment of loans by subsidiaries	-	3,339	-	3,339	4,622
Net cash provided by (used in) investment activities	(2,369)	5,108	(1,652)	8,308	80
Cash flows from financing activities					
Purchase of shares of investee company	-	(192)	-	(192)	(192)
Dividend paid to the Company's shareholders	-	-	-	-	(15,000)
Receipt of long-term loans from banks	-	5,000	-	5,000	5,000
Repayment of loans from banks	-	-	-	-	(1,000)
Proceeds from exercise of options	44	-	-	-	331
Net cash provided by (used in) financing activities	44	4,808	-	4,808	(10,861)
Increase (decrease) in cash and cash equivalents	(4,356)	17,178	(3,309)	21,246	(5,940)
Cash and cash equivalents as of beginning of the period	25,097	31,037	24,050	26,969	31,037
Cash and cash equivalents as of end of the period	20,741	48,215	20,741	48,215	25,097

The accompanying additional information is an integral part of the separate financial data and information.

ADDITIONAL INFORMATION

U.S.D in thousands

1. General

The accompanying condensed separate financial data as of June 30, 2013 and for the six and three months then ended, have been prepared in accordance with Regulation 38D of the Israel Securities Regulations (Periodic and Immediate Reports) – 1970. The accompanying separate financial data should be read in conjunction with the Company's consolidated financial statements for 2012 and the Company's interim consolidated financial statements and accompanying notes.

2. Other long term liabilities

Other long term liabilities include liabilities towards Elbit Ltd. ("Elbit") which is a fully owned subsidiary of Elron. Such liabilities include non-interest bearing and unlinked NIS capital notes. The exchange differences in regards with these capital notes are included under financial income or expenses in the income statement.

Elron Electronic Industries Ltd.

Part IV

**English Translation of Quarterly Report
regarding the Effectiveness of the Internal
Control over Financial Reporting and
Disclosure pursuant to Regulation 38C:**

As of June 30, 2013

Attached herein is a quarterly report regarding the effectiveness of internal control over financial reporting and disclosure, pursuant to Regulation 38C of the Israel Securities Regulations (Periodic and Immediate Reports), 5730-1970:

Quarterly report regarding the effectiveness of the internal control over financial reporting and disclosure, pursuant to Regulation 38C(a):

Management, under the supervision of the board of directors of Elron Electronic Industries Ltd. (the "**Corporation**"), is responsible for establishing and maintaining adequate internal controls over the financial reporting and disclosure in the Corporation.

In this regard, the members of management are:

1. Mr. Ari Bronshtein, CEO;
2. Mr. Yaron Elad, CFO.

The Corporation's internal control over financial reporting and disclosure is a process designed by, or under the supervision of, the Corporation's principal executive and principal financial officer, or persons performing similar functions, and under the board of directors' supervision, that is meant to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with the provisions of the law, and to ensure that the information that the Corporation is required to disclose in its reports according to the provisions of the law is recorded, processed, summarized and reported in a timely manner, in the format prescribed by law.

The internal control includes, inter alia, controls and procedures which were designed to ensure that information which the Corporation is required to disclose as aforesaid, is recorded and made available to the Corporation's management, including the principal executive officer and principal financial officer, or persons performing similar functions, as necessary to permit the timely adoption of resolutions pertaining to disclosure requirements.

Because of its inherent limitations, internal control over financial reporting and disclosure is not intended to provide absolute assurance regarding prevention or detection of misstatements or omissions.

In the quarterly report on the effectiveness of the internal control over financial reporting and disclosure which was attached to the quarterly report for the period ended March 31, 2013 (the "**Last Quarterly Report Regarding the Internal Control**"), the internal control was deemed effective.

Up until the date of this report, no event or matter was brought to the attention of management or the board of directors which would change the assessment of the effectiveness of the internal control, as set forth in the Last Annual Report Regarding the Internal Control.

As of the date of this report, based on the Last Quarterly Report Regarding the Internal Control, and based on information which was brought to the attention of management and the board of directors as aforesaid, the internal control is effective.

Declaration of the Principal Executive Officer pursuant to Regulation 38C(d)(1):

Managers' Declaration

Declaration of the Chief Executive Officer

I, Ari Bronshtein, declare that:

- (1) I have examined the quarterly report of Elron Electronic Industries Ltd. (the "**Corporation**") for the second quarter of 2013 (the "**Reports**");
- (2) Based on my knowledge, the Reports do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Reports;
- (3) Based on my knowledge, the financial statements and other financial information included in the Reports, fairly present, in all material respects, the financial condition, results of operations and cash flows of the Corporation, as of, and for the periods presented in the Reports;
- (4) I have disclosed to the Corporation's independent auditors, board of directors and audit committee of the Corporation's board of directors, based on my most recent assessment of internal control over financial reporting and disclosure:
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting and disclosure, which are reasonably likely to adversely affect the Corporation's ability to record, process, summarize or report financial information in a manner which may cast doubt on the reliability of the financial reporting and preparation of the financial statements in accordance with the provisions of the law; and –
 - (b) Any fraud, whether or not material, which involves the principal executive officer, a direct subordinate of the principal executive officer, or other employees who have a significant role in the internal control over financial reporting and disclosure.
- (5) I, alone or together with others in the Corporation, have:
 - (a) Designed such controls and procedures, or caused such controls and procedures to be designed and maintained under my supervision, to ensure that material information relating to the Corporation, including its consolidated subsidiaries as defined in the Israel Securities Law (Annual Financial Statements), 5770-2010, is made known to me by others within the Corporation and the consolidated subsidiaries, particularly during the period in which the Reports are being prepared; and –
 - (b) Designed such controls and procedures, or caused such controls and procedures to be designed and maintained under my supervision, to reasonably ensure the reliability of the financial reporting and preparation of the financial statements in accordance with the provisions of the law, including in accordance with GAAP;
 - (c) No event or matter was brought to my attention during the period between the date of the last report (quarterly or periodic, as relevant) and the date of this report, which would change the conclusion of the board of directors and management regarding the effectiveness of the internal control over financial reporting and disclosure of the Corporation.

Nothing in the aforesaid derogates from my responsibility or the responsibility of any other person, pursuant to any law.

August 13, 2013 _____

Ari Bronshtein, CEO

Declaration of the Principal Financial Officer pursuant to Regulation 38C(d)(2):

Managers' Declaration

Declaration of Principal Financial Officer

I, Yaron Elad, declare that:

- (1) I have examined the interim financial statements and other financial information which is included in the interim reports of Elron Electronic Industries Ltd. (the "**Corporation**") for the second quarter of 2013 (the "**Reports**" or the "**Interim Reports**");
- (2) Based on my knowledge, the interim financial statements and other financial information which is included in the Interim Reports do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Reports;
- (3) Based on my knowledge, the interim financial statements and other financial information included in the Interim Reports fairly present, in all material respects, the financial condition, results of operations and cash flows of the Corporation, as of, and for the periods presented in the Reports;
- (4) I have disclosed to the Corporation's independent auditor, board of directors and the audit committee of the Corporation's board of directors, based on my most recent assessment of internal control over financial reporting and disclosure:
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting and disclosure, insofar as the same refers to the interim financial statements and other financial information which is included in the Interim Reports, which are reasonably likely to adversely affect the Corporation's ability to record, process, summarize or report financial information in a manner which may cast doubt on the reliability of the financial reporting and preparation of the financial statements in accordance with the provisions of the law; and –
 - (b) Any fraud, whether or not material, which involves the principal executive officer, a direct subordinate of the principal executive officer, or other employees who have a significant role in the internal control over the financial reporting and disclosure.
- (5) I, alone or together with others in the Corporation, have:
 - (a) Designed controls and procedures, or caused such controls and procedures to be designed and maintained under our supervision, to ensure that material information relating to the Corporation, including its consolidated subsidiaries as defined in the Israel Securities Law (Annual Financial Statements), 5770-2010, is made known to me by others in the Corporation and the consolidated subsidiaries, particularly during the period in which the Reports are being prepared; and –
 - (b) Designed such controls and procedures, or caused such controls and procedures to be designed and maintained under my supervision, to reasonably ensure the reliability of the financial reporting and preparation of the financial statements in accordance with the provisions of the law, including in accordance with GAAP;
 - (c) No event or matter was brought to my attention during the period between the date of the last report (quarterly or periodic, as relevant) and the date of this report, relating to the interim financial statements and other financial information included in the Interim Reports, which would change, in my assessment, the conclusion of the board of directors and management regarding the effectiveness of the internal control over financial reporting and disclosure of the Corporation.

Nothing in the aforesaid derogates from my responsibility or the responsibility of any other person, pursuant to any law.

August 13, 2013 _____

Yaron Elad, CFO

Liabilities report of the Company by repayment date
Section 36a to the Israel Securities Law (1968)

Report as of June 30, 2013

Following are the liabilities of the Company by repayment date:

The following data are presented in NIS and were translated from USD to NIS using the exchange rate as of June 30, 2013 (1 USD = 3.618 NIS)

A. Debentures issued to the public by the reporting Entity and held by the public, excluding debentures held by the Company's parent, controlling shareholder, companies controlled by one of the parties mentioned above or by companies controlled by the company - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

B. Private debentures and non-bank credit, excluding debentures or credit granted by the Company's parent, controlling shareholder, companies controlled by one of the parties mentioned above or by companies controlled by the company - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

C. Bank credit from Israeli banks - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

D. Bank credit from non-Israeli banks - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	579
Second year	0	0	0	14,472	0	474
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	14,472	0	1,053

E. Summary of tables A-D, totals of: bank credit, non-bank credit and debentures - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	579
Second year	0	0	0	14,472	0	474
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	14,472	0	1,053

F. Off-balance credit exposure - based on separate financial data of the Entity ("Solo" reports) (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

G. Off-balance credit exposure of all consolidated companies, excluding companies that are considered as reporting companies, and excluding the reporting Company's data described above in Table F (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

H. Totals of: bank credit, non-bank credit, and debentures of all consolidated companies, excluding companies that are considered as reporting companies and excluding the data of the reporting Entity described above in Tables A-D (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	3,455	0
Total	0	0	0	0	3,455	0

I. Total credit granted to the reporting Entity by the parent company or controlling shareholder, and total amounts of debentures issued by the reporting Entity that are held by the parent company or controlling shareholder (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

J. Credit granted to the reporting Entity by companies controlled by the parent company or by the controlling shareholder, and are not controlled by the reporting Entity, and debentures issued by the reporting Entity held by companies controlled by the parent company or by controlling shareholder and are not controlled by the reporting Entity (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

K. Credit granted to the reporting Entity by consolidated companies and debentures issued by the reporting Entity held by consolidated companies (NIS in thousands)

	Principle repayment					Gross interest payments (excluding deduction of tax)
	NIS (CPI linked)	NIS (Not linked)	Euro	USD	Other	
First year	0	0	0	0	0	0
Second year	0	0	0	0	0	0
Third year	0	0	0	0	0	0
Fourth Year	0	0	0	0	0	0
Fifth year and thereafter	0	0	0	0	0	0
Total	0	0	0	0	0	0

L. (1) Cash and cash equivalents, marketable securities and short-term deposits based on the Company's separate financial data (NIS in thousands)

75,041

(2) Cash and cash equivalents, marketable securities and short-term deposits based on the Company's consolidated Statements (NIS in thousands)

150,784

